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Abstract. Alzheimer’s disease (AD) and frontotemporal dementia (FTD) represent the first cause of dementia in senile
and pre-senile population, respectively. A percentage of cases have a genetic cause, inherited with an autosomal dominant
pattern of transmission. The majority of cases, however, derive from complex interactions between a number of genetic and
environmental factors. Gene variants may act as risk or protective factors. Their combination with a variety of environmental
exposures may result in increased susceptibility to these diseases or may influence their course. The scenario is even more
complicated considering the effect of epigenetics, which encompasses mechanisms able to alter the expression of genes
without altering the DNA sequence. In this review, an overview of the current genetic and epigenetic progresses in AD
and FTD will be provided, with particular focus on 1) causative genes, 2) genetic risk factors and disease modifiers, and
3) epigenetics, including methylation, non-coding RNAs and chromatin remodeling.
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INTRODUCTION
Most neurological disorders, including
Alzheimer’s disease (AD) and frontotemporal
dementia (FTD), are multifactorial diseases. Despite
a small percentage of these diseases occurring in
families with an autosomal dominant pattern of
transmission, the majority of cases are sporadic, and
derive from complex interactions between a number
of genetic and environmental factors. Therefore,
these diseases are defined as “multifactorial” or
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“complex” [1]. The familial clustering can be
explained by recognizing that family members share
a greater proportion of their genetic information and
environmental exposures than do individuals chosen
randomly in the population. Thus, the relatives of
an affected individual are more likely to experience
the same gene-gene and gene-environment inter-
actions that led to disease in the first place than
are individuals who are unrelated to the patient.
The multifactorial inheritance pattern represents
an interaction between the collective effect of the
genotype at one or, more commonly, multiple loci
(polygenic or multigenic effects) either to increase
or to decrease the susceptibility to the disease,
combined with a variety of environmental exposures
that may trigger, accelerate, or protect against the
disease altered mechanisms.
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The gene-gene interactions in polygenic inheri-
tance may be simply additive or more complicated.
Gene-environment interactions, including systematic
exposures or chance encounters with environmental
factors in one’s surroundings, add even more com-
plexity to individual disease risk and the pattern of
disease inheritance.
Herein, main genetic variations, either causative
or conferring risk for AD and FTD will be described,
together with epigenetic factors.
GENETICS: BASIC CONCEPTS AND
METHODOLOGIES
Genetic background differs from thousands to mil-
lions of genetic variants that are the differences in
DNA sequences within the genome of individuals
in the population. These variations can take many
forms, including single nucleotide polymorphisms
(SNPs), tandem repeats (short and variable), small
insertions and deletions, duplications or deletions that
change the copy number of a large segment of a
DNA sequence (≥1 kb), i.e., copy number variations
(CNVs), and other chromosomal rearrangements
such as inversions and translocations (also known as
copy-neutral variations) [1–3].
Common variants are synonymous with polymor-
phisms, defined as genetic variants with a minor allele
frequency (MAF) of at least one percent in the pop-
ulation, whereas rare variants have a MAF of less
than 1% [1]. The large majority of genetic variants
are hypothesized to be neutral [4], as they do not
contribute to phenotypic variation.
Four strategies have been applied so far in genetic
studies: genetic linkage analysis, candidate gene
studies, genome wide association studies (GWAS),
and next generation sequencing (NGS) technology
based studies: whole genome sequencing (WGS) and
whole exome sequencing (WES).
Linkage analyses were the first kind of strategy
used to unravel the genetic basis of Mendelian traits,
involving families presenting autosomal dominant
inheritance. Genetic linkage studies led to the identi-
fication of chromosomal regions associated with the
disease segregation, but does not identify the causal
gene associated, which requires fine mapping [5].
The candidate gene approach aims to determinate
whether frequencies of genetic variants of people
with a specific disease differ significantly from a con-
trol population. Susceptibility genes are defined when
cases and controls showed significant differences
in occurring genetic variants frequencies. Candi-
date gene approach led to the identification of the
Apolipoprotein E gene (APOE) risk alleles impli-
cated in late onset AD (LOAD). Thousands of genes
were tested in this way on the basis of existing
knowledge on disease pathogenesis, quite often giv-
ing inconsistent results, particularly because most of
the candidate gene association studies could not be
replicated, due to the small sample size, which did
not allow adequate statistical power [6].
The advent of microarray technology era revolu-
tionized genetics research, allowing the contempora-
neous determination of millions of SNPs in thousands
of samples. GWAS are based on the testing common
genetic variants in a hypothesis-free manner. Thus,
it provides information on how common genetic
variability confers risk for common diseases [7].
Several susceptibility genes for common neurode-
generative disorders have been revealed by GWAS
studies, although the odds ratios associated with these
risk alleles are relatively low [8].
Recent advances, collectively referred to as NGS,
allowed for high-throughput sequencing, giving mas-
sive data results, that need to be analyzed by specific
bioinformatics software. Moreover, in opposition to
the first generation sequencing, NGS can produce the
same genome sequence within a few weeks and with
reduced costs. This allows for simultaneous investi-
gation of multiple genes and has been demonstrated to
be an effective alternative for establishing the genetic
base for Mendelian diseases in the research setting
[9, 10] and recently also in clinical settings [11,
12]. NGS relies upon multiple, short, overlapping
reads of fragmented DNA that can be aligned against
a reference genome or assembled “de novo” if no
information on the reference genome is available. If
just the protein-coding regions are amplified when
sequencing all the genes, the method is referred to as
WES, whereas when the target is the whole genome,
it is known as WGS.
GENETICS OF ALZHEIMER’S DISEASE
AD is a multifactorial and complex neurodegen-
erative disorder and the leading cause of dementia
among elderly people. Genetically, AD can be subdi-
vided into a rare familial form, accounting for 2-3%
of all patients presenting with autosomal dominant
inheritance, and a multifactorial sporadic form in
which specific environmental exposures in combi-
nation with genetic susceptibility contribute to the
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exacerbation of the disease [1]. Genetically inherited
AD usually develops before 65 years of age early
onset AD (EOAD), whereas the sporadic type of dis-
ease often occurs later in life in individuals older than
65 years and is referred as LOAD [13].
Three genes, discovered thanks to linkage anal-
ysis, are responsible for familial AD: Presenilin 1
(PSEN1), Presenilin 2 (PSEN2), and Amyloid pre-
cursor protein (APP). They map on three different
chromosomes, but share a common biological path-
way related to amyloid processing [14]. A number
of variants in these genes have been described,
the majority of which play a causal role in the
pathogenesis of the disease (see [15] for details).
The proportion of cases of autosomal dominant
AD explained by mutations in these genes is high
but vary widely from 12% to 77% [16, 17], suggest-
ing that there are additional genetic factors involved
in the pathogenesis of EOAD. Recently, thanks to
the NGS approach, some new genetic variants were
found in small families with unexplained EOAD.
Guerreiro et al. [18] identified a missense mutation in
NOTCH3 (R1231C), that is a gene previously linked
to cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy. Never-
theless, complete screening of NOTCH3 in a cohort
of 95 EOAD cases and 95 controls did not reveal any
additional pathogenic mutations [18].
Another study [19] identified mutations in the Sor-
tilin related receptor 1 (SORL1) gene in EOAD.
This gene encodes a neuronal sorting protein able
to bind APP, driving it toward the endosome-
recycling pathways [19]. Other studies involving
EOAD found association between the Triggering
Receptor Expressed on Myeloid cells 2 (TREM2)
gene and the risk of develop the disease. TREM2
is an immune phagocytic receptor expressed in brain
microglia, able to modulate microglial phagocytosis
and inflammatory pathway [20].
By using a NGS WES based approach, an associ-
ation between TREM2 variants in exon 2 and EOAD
in Caucasian subjects of French origin was identified.
In particular, an association between rs75932628T
allele (R47H) and the risk of developing the disease
was described [21]. The same variant was further con-
firmed to be a risk factor for EOAD in a recent study
[22], which showed that individuals with the R47H
variant had significantly earlier symptom onset than
individuals without TREM2 variants [22]. TREM2
genetic variability has been investigated also with
regard of LOAD susceptibility by different groups.
Jonsson et al. [23] found that the rs7593628T in
TREM2 confers a significant threefold increased risk
for AD in a cohort of Icelanders. The same variant was
further tested by Guerreiro et al. [24] by WES and was
found to cause a five-fold increased risk to develop
AD. Furthermore, six additional TREM2 variants
were found in AD but not in controls, highlighting
their possible consistent contribution to increase AD
risk [25]. In this study, the protective rs728224905 in
PLCG2 and the risk variant rs616338 in ABI3 gene
were also associated with AD, suggesting an impli-
cation of microglial-mediated innate immunity in the
pathogenesis of the disease [25].
A recent study [26] identified, by GWAS, a novel
missense mutation in phospholipase D family mem-
ber 3 gene (PLD3) in an EOAD autopsy-confirmed
patient. However, further confirmatory analysis in
larger populations of European EOAD did not lead to
significant evidence for an enrichment of rare PLD3
variants [26]; therefore the genetic role of PLD3 in
AD remains to be demonstrated. The use of NGS
with a target panel able to analyze 10 genes involved
in dementia led instead to the identification of novel
coding variants in PSEN1, predicted to be pathogenic
[27].
Recent GWAS studies [28, 29] confirmed that
APOE 4 remains the single most important genetic
risk factor for AD (see [30] for review), although
about additional ten risk factors emerged recently as
strongly associated with LOAD [29, 30]. Notably, the
majority of such AD susceptibility loci (CLU, BIN1,
CR1, ABCA7, CD33, EPHA1) have putative func-
tions in lipid metabolism and immune system [30]
(Table 1).
Table 1
Causal genes and genetic risk factors for AD
Causal genes Chromosome Function
APP 21 Amyloid precursor protein
PSEN1 14 APP cleavage
PSEN2 1 APP cleavage
Risk factors Chromosome Function
APOE 19 Lipid metabolism
TREM2 6 Innate immunity; expressed
by microglia
BIN1 2 Nucleocytoplasmic adaptor
protein
CLU 8 Lipid metabolism
ABCA7 19 Lipid homeostasis in cells of
the immune system
CR1 1 Immune response
PICALM 11 Membrane metabolism
MS4A6A 11 Transmembrane protein
CD33 19 Membrane antigen
MS4A4E 11 Transmembrane protein
CD2AP 6 Cytoskeleton dynamics
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A rare variant is the Nicastrin gene, recently iden-
tified by NGS as risk factor for LOAD in a Greek
population [31].
Lastly, Kohli and colleagues, using WES on 11
affected individuals in a large kindred with appar-
ent autosomal dominant LOAD, found damaging
missense mutations in the Tetratricopeptide repeat
domain 3 gene (TTC) in all affected individuals [32].
GENETICS OF FRONTOTEMPORAL
DEMENTIA: MAJOR CAUSAL GENES
The majority of FTD cases are sporadic and likely
caused by the interaction between genetic and envi-
ronmental factors. A number of cases, however,
present familial aggregation and are inherited in an
autosomal dominant fashion, suggesting a genetic
cause [32–34]. Up to 40% of patients have a posi-
tive family history, with a diagnosis of dementia in at
least one extra family member [33, 35]. At present,
three major causal genes have been identified: Micro-
tubule Associated Protein Tau (MAPT), Progranulin
(GRN), and Chromosome 9 Open Reading Frame 72
(C9ORF72). In addition, some rare causal genes have
been identified (Table 2).
MAPT
The first evidence of a genetic cause for famil-
ial FTD came from the demonstration of a linkage
with chromosome 17q21.2 in autosomal dominantly
inherited form of FTD with parkinsonism [36],
named FTDP-17. The gene responsible for such asso-
ciation, MAPT, was discovered few years later [37].
MAPT encodes the protein tau, which is involved in
microtubule stabilization, assembly, and cytoskele-
tal dynamics [38]. It is composed of 15 exons and
transcribed, by alternative splicing, in 6 different iso-
forms, all of which play a role in the maintenance
of microtubular structure. Any excess of tau protein
can be bundled into protein aggregates that fill the
cells and induce neurotoxicity. Tau has four repeat
domains in the C-terminus, which mediate the inter-
action with microtubules. These domains are encoded
by exons 9–12, in which the majority of pathogenic
mutations have been found. In addition, alternative
splicing of exon 10 leads to two different isoforms
that contain either three (3R) or four (4R) 31-amino
acids repeats [39].
The pathology of all MAPT mutations is charac-
terized by the deposition of insoluble aggregated tau
proteins within neurons and glial cells in the cerebral
cortex and in other brain regions.
To date, more than 40 pathogenic MAPT mutations
have been described and classified according to their
position in the gene [40], their effects on MAPT tran-
scription, and the type of tauopathy. The frequency
of MAPT mutations is highly variable, but in general
MAPT mutations are very rare in sporadic patients,
whereas in most familial cases the frequency ranges
between 5% and 20% depending on the geographic
distribution [41].
The pathogenic mechanism of each different muta-
tion depends on the type and location of the genetic
defect, and affects the normal function of tau, i.e., the
stabilization of microtubules promoting their assem-
bly by binding tubulin. Some mutations increase the
free cytoplasmic portion of the protein promoting
Table 2
Causal genes and genetic risk factors for FTD
Causal genes Chromosome Function
MAPT 17 Microtubule stabilization, assembly and cytoskeletal dynamics
GRN 17 Inflammation
C9ORF72 9 Nucleocytoplasmic transport, autophagy, intercellular trafficking
CHMP2B 3 Autophagy, protein trafficking and degradation
VCP-1 9 Autophagy, protein trafficking and degradation
SQSTM1 5 Encodes for p62, autophagy, protein degradation
CHCHD10 22 Mitochondrial protein
TBK1 12 Autophagy, protein trafficking and degradation
TARDBP 1 Encodes for TDP-43, transcription factor
FUS 16 Encodes for FUS, transcription factor
UBQLN2 X Autophagy, protein trafficking and degradation
TUBA4A 2 Cytoskeletal dynamics
Risk Factors
TMEM106B 11 Transmembrane protein
GRN 17 Inflammation
RAB8/CTSC 11 Lysosomal biology and protein trafficking
HLA 6 Immune system
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tau aggregation, while others lead to an aber-
rant phosphorylation of tau protein, which damages
microtubule stabilization [41]. Regarding mutations
localized in the donor splicing site following exon 10,
it was shown that these intronic mutations increase
the inclusion of MAPT exon 10 by destabilizing the
stem-loop structure that spans the splice site of exon
10, resulting in an increased production of 4R tau.
Mutations in the acceptor splicing site following exon
10 lead to an enhanced inclusion of this exon [42].
Alternatively, other mutations affect the alternative
splicing, thus producing altered ratios of the different
isoforms (3R/4R tau). Most of missense mutations,
such as the p.P301L mutation, reduce the ability
of tau to bind microtubules leading to a decreased
tau capacity to promote microtubules assembly [43].
Moreover, it was observed in in vitro studies that
several coding mutations accelerate the aggregation
of tau [44]. In 2009, Rovelet-Lecrux and coworkers
identified a heterozygous 17.3 Kb deletion responsi-
ble for the removal of exons 6–9 of MAPT in one FTD
patient [45]. This deletion caused the loss of the first
microtubule binding domain and a decrease in the
binding abilities of tau to the microtubules. The same
group reported a 439 Kb duplication in the region
encompassing CRHR1, MAPT, and saithoin (STH)
in one patient affected by behavioral and amnestic
disorders [46].
The clinical presentation in MAPT mutation car-
riers is heterogeneous, but behavioral changes,
semantic impairment, episodic memory decline, and
parkinsonism have been proposed as key clinical fea-
tures. From the pathological point of view, patients
present atrophy of the frontotemporal lobes and
basal ganglia and variable presences of tau-positive
inclusions, typical of FTLD-tau [47].
GRN
After the discovery of MAPT as causal gene for
FTDP-17, there were still numerous autosomal dom-
inant FTD cases genetically linked to the same
chromosomal region of MAPT (chr17q21), without
any mutation in MAPT, in spite of an extensive fine
mapping of the gene. A small region rich in genes,
localized approximately 6.2 Mb in physical distance
to MAPT locus, had been recognized as that one con-
taining the gene responsible for the disease in these
families. The first identified mutation in GRN, iden-
tified in 2006, consisted of a 4-bp insertion of CTGC
between coding nucleotides 90 and 91, causing a
frameshift and premature termination in progranulin
(C31LfsX34) [48]. In a parallel study, Cruts and co-
workers found at the same time another mutation
of five base pairs into the intron following the first
non-coding exon of GRN (IVS1+5G>C) [49]. This
mutation causes the splicing out of the intron 0, lead-
ing the retention of mRNA within the nucleus and its
degradation.
GRN mutations were subsequently found to
account for 5–20% of FTD patients with positive fam-
ily history and 1–5% of apparently sporadic patients
[50].
GRN encodes for the growth regulation factor
named progranulin. Progranulin is an 88 kDa secreted
glycoprotein, which in brain is expressed by neu-
rons and microglia [51]. Its expression is low in
early development and increases with age. The pro-
tein is composed by seven and one half cysteine-rich
granulin domains and can be cleaved by several pro-
teases into 6 KDa units called granulins. It belongs to
a family of proteins involved in multiple biological
functions, including development, wound repair, and
inflammation, by activating signaling cascades that
control cell cycle progression and cell motility [51].
Since the original identification of null-mutations
in FTLD, more than 70 different mutations have
been described so far. Most of the known pathogenic
GRN mutations, particularly frameshift, splice-site,
and nonsense mutations, are predicted to result in a
premature stop codon. The resulting aberrant mRNA
is degraded through the process of nonsense medi-
ated decay, leading to haploinsufficiency [52]. Also
rare partial deletions and a complete deletion of the
gene have been described [53].
At neuropathological examination, GRN-mutated
FTD cases displayed ubiquitin-positive, tau-negative
inclusions (FTLD-U) similar to the microvacuolar-
type still observed in a large proportion of apparently
sporadic FTD, that were different from the tau-
positive inclusions typical of MAPT mutated cases.
Truncated and hyperphosphorylated isoforms of the
TAR DNA binding Protein (TDP-43) were recog-
nized as main components of the ubiquitin-positive
inclusions typical of the GRN mutated families, as
well as of idiopathic FTD and of a proportion of
cases of amyotrophic lateral sclerosis (ALS) [54].
According to the novel neuropathological classifica-
tion of FTLD-TDP pathology in FTD [55], TDP-43
neuropathological subtype A is consistently found in
association with GRN-mutated cases.
A collaborative study [53] analyzing GRN muta-
tions in 434 patients estimates a frequency of 6.9% of
all included FTD-spectrum cases. About 56% of such
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cases was represented by FTD subjects with ubiquiti-
nated inclusions at the neuropathology (FTD-U) with
a positive family history of FTD.
From the clinical point of view, mutations in GRN
are associated with extremely heterogeneous phe-
notypes, but the main clinical diagnosis is FTD
following by diagnosis of primary progressive apha-
sia [56]. Language impairment seems to be more
relevant as the disease progresses. About 40% of
patients have parkinsonism, and episodic memory
impairment is frequently observed, leading to a clin-
ical diagnosis of AD in some cases [57]. Although
rarely, an overlap between psychiatric disorders and
genetically determined FTD can occur, as shown
by Rainero et al. [58], who described a patient
with heterosexual pedophilia who was a carrier of
a GRN mutation and developed FTD over time, and
by Cerami et al. [59], who reported two clinically
different, apparently sporadic FTD cases sharing
the Thr272fs GRN mutation, who had a premorbid
bipolar disorder history.
The penetrance for GRN mutations is age depen-
dent with only 50% ofGRNmutation carriers affected
at the age of 60 and 90% of mutation carriers affected
at 70 years of age. Age at disease onset is extremely
wide, even in the same family, ranging from 47 to
79 years [60]. In a large Calabrian family harbor-
ing a heterozygous c.1145insA mutation, the age at
onset ranged from 35 to 87 years whereas the age
of death was from 56 to 87 years [61]. In that fam-
ily, the clinical presentation was homogenous; all of
affected members had clinical diagnosis of FTD with
subsequent language impairment.
A major contribution to achieve a correct diag-
nosis independent of the phenotypic presentation is
the demonstration that progranulin plasma levels are
extremely low in GRN mutation carriers, even in
asymptomatic subjects [62, 63].
Regarding the function of progranulin, Pickford
et al. [64] demonstrated, in an in vitro model,
that it has chemotactic properties toward cultured
mouse neurons. In addition, progranulin-treated
primary neurons secrete a number of cytokines
and chemokines, particularly those involved in
proliferation (i.e., IL-4), and, importantly, induce
microglia to switch from a pro-inflammatory to an
anti-inflammatory phenotype [64]. Another recent
observation is that progranulin binds the Tumor
Necrosis Factor Receptor (TNFR)2, that is expressed
specifically in neuronal subtypes and glial cells
in the brain, leading to an anti-inflammatory cascade
[65].
Abnormalities of several cytokines and
chemokines has been observed in cerebrospinal fluid
(CSF) of GRN carriers compared with controls [66],
suggesting an imbalance of specific inflammatory
factors possibly related to GRN haploinsufficiency.
C9ORF72
One of the most intriguing discoveries in the genet-
ics of FTD has been the investigation of FTD/motor
neuron disease (MND) families linked to a locus on
chromosome 9q21-22. The first evidence of linkage
with this locus comes from a study carried out in
families with autosomal dominant FTD-MND [67].
Additional data confirmed the linkage to chr9q21-22
in FTD-MND families [68], until, in 2011, two inter-
national groups identified the gene responsible for the
disease in this locus, C9ORF72 [69, 70]. The muta-
tion consists of a large hexanucleotide (GGGGCC)
repeat expansion in the first intron of the gene.
In healthy subjects, most individuals carry between
2 and 20 repeats, but FTD and ALS patients had from
100 to also 1000 s of copies of repeats. The minimum
repeat length to confer risk of disease is unknown,
probably due to the presence of somatic mosaicism.
In fact, the length of repeats is different between tis-
sues even in the same individual and this phenomenon
complicates genotype-phenotype correlation studies
[71].
C9ORF72 repeat expansion is the most common
cause of FTD (with or without ALS) worldwide.
There is a particular high frequency in a Finland pop-
ulation, probably due to a common founder. Studies
in Asian cohorts have reported instead much lower
frequencies [72].
Clinical phenotypes are very variable [73] as well
as the age at onset and disease duration; in fact, age
at onset can range between 27 and 83 years and
disease duration from 1 to 22 years. The most com-
mon clinical presentation is FTD, ALS, or both. As
mentioned above, in families where FTD-ALS is the
clinical phenotype, the C9ORF72 repeat expansion
is very common, explaining the disease in more than
50% of families [74]. FTD patients present behav-
ioral disturbances, whereas language impairment is
less commonly observed [75]. In addition to classical
behavioral presentations, such as apathy, disinhi-
bition, socially inappropriate conduct, and loss of
empathy, C9ORF72 expansion carriers present a high
frequency of hallucinations, psychosis, and delusions
[76], which lead to a primary diagnosis of schizophre-
nia and bipolar disorders [77, 78]. Sometimes patients
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have episodic memory problems at the beginning
of the disease course, receiving a primary diagnosis
of AD [76, 79]. Less than 1% of clinically diag-
nosed AD patients carry a C9ORF72 expansion with
TDP43 pathology [79]. Other studies [80] found no
C9ORF72 expansions in AD patients, suggesting the
total frequency of C9ORF72 positive cases in AD
is very rare (<1%). Most likely, there is no associa-
tion between AD and C9ORF72. Likely, some AD
cases have been misdiagnosed or some expansions
are not big enough to be causal. Early-parkinsonism
has also been reported in C9ORF72 expansion carri-
ers, although very rarely in MAPT and GRN mutation
carriers [76].
From a neuropathological point of view, post-
mortem examination showed that C9ORF72 expan-
sion carriers present TDP-43 positive inclusions in
different brain areas. Most patients present with
FTLD-TDP type A or B [55]. In addition, they
have neuronal inclusions in the cerebellar granule
cell layer, hippocampal pyramidal neurons, and other
anatomic sites that are positive for ubiquitin and
p62 proteins. These inclusions are composed by
dipeptide repeat proteins (DPRs), translated from
the GGGGCC repeat through unconventional repeat-
associated non-ATG translation. Poly-GP, Poly-GA,
and Poly-GR are generated from sense strand and
detected in hippocampus and cerebellum of expan-
sion carriers [81]. Normal C9ORF72 functions were
reported to be involved in the nucleocytoplasmic
transport, autophagy, intercellular trafficking, and
TDP-43 aggregation (see [82] for review).
Reddy et al. [83] demonstrated that the
r(GGGGCC)n RNA forms extremely stable G-
quadruplex structures, which theoretically may
affect promoter activity, genetic instability, RNA
splicing, translation and neurite mRNA localization.
Moreover, several studies, conducted in derived
cells and tissue of patients, demonstrated that these
foci are able to sequester RNA binding protein,
including hnRNP h, hnRNP A1, and SC35, affecting
the mRNA nuclear transport system [84]. How-
ever, the clear mechanism linking RNA foci and
sequestered proteins to neurodegeneration has not
been fully understood. Together with the forma-
tion of RNA foci and DPR, another suggested
pathological mechanism of the C9ORF72 expan-
sion is gene downregulation due to C9ORF72
methylation [85].
In cultured cells and primary neurons, Poly-GA
overexpression led to the generation of p62-positive
inclusions and neurotoxicity attributed to impaired
ubiquitin proteasome function [86]. On the other
hand, arginine-rich dipeptide (poly-GR and poly-
PR) led to the formation of nucleolar inclusions
in fly models [87]. Since the clinical utility as
well as the significance and the temporal course
of DPRs in the pathogenesis of the disease is still
unclear, Lehmer et al. [88] established a poly-GP
immunoassay from CSF in order to identify and
characterize C9ORF72 patients. Intriguingly, they
observed Poly-GP CSF levels were already detectable
in C9ORF72 asymptomatic carriers compared to
healthy subjects and these levels are similar in symp-
tomatic expansion carriers, demonstrating a possible
use as a diagnostic biomarker in addition to genetic
screening [88].
GENETICS OF FRONTOTEMPORAL
DEMENTIA: RARE CAUSAL GENES
CHMP2B
Few FTLD families display mutations in the
charged multivesicular body protein 2B gene
(CHMP2B), which encodes a component of the
heteromeric ESCRT III complex, involved in
the endosomal trafficking and degradation [89].
CHMP2B is involved in sorting and trafficking sur-
face receptors or proteins into intraluminal vesicles
for lysosomal degradation and binding the Vps4
protein responsible for the dissociation of ESCRT
components [90]. The first mutation in CHMP2B
was identified in one large kindred from Denmark
[91]. Behavioral and cognitive impairment associated
with extrapyramidal and pyramidal signs are the main
clinical manifestations in CHMP2B.
All mutations described (missense and truncation
mutations) show a common mechanism of action: the
deletion of the C-terminus of the protein with the loss
of the Vsp-4 binding domain [90]. This causes the
accumulation of mutated CHMP2B on the endosomal
membrane and prevent the recruitment of other pro-
teins necessary for endosomal fusion with lysosomal.
This phenomenon leads to the impairment of the late
endosomal trafficking and contributes to neurodegen-
erative processes in FTD [91]. This can be observed
as enlarged and abnormal endosomal structures in
postmortem brain tissue from patients [92]. From a
histological point of view, patients with CHMP2B
mutations present FTLD-U with ubiquitin- and p62-
positive but TDP-43-negative neuronal cytoplasmic
inclusions [93].
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VCP-1 and SQSTM1
Mutations in the Valosin Containg Protein gene
(VCP) were firstly described as cause of hereditary
inclusion body myopathy with Paget’s disease of the
bone (PDB) and FTD [94]. Myopathy is the most
frequent clinical symptom, present in about 90% of
affected subjects, whereas FTD is seen in about 33%,
usually many years after the onset of muscle symp-
toms. From a histological point of view, brain tissues
of patients carrying VCP mutations are characterized
by FTLD-TDP type D pathology with TDP43 and
p62 positive inclusions within neuronal nuclei [95].
VCP-1 encodes a monomeric protein composed of
806 aminoacids. It is known as a regulator of many
cellular processes, such as ubiquitin-dependent pro-
tein quality control, labeling proteins for degradation,
and coordination of the removal of protein aggregates
via multivesicular body formation [96].
Another gene involved in the mechanism of pro-
tein degradation as well as in FTLD pathogenesis is
Sequestosome 1 gene (SQSTM1). This gene encodes
for p62 protein, a connector between ubiquiti-
nated proteins and autophagy receptor or proteasome
degradation pathways [97]. Mutations in SQSTM1
were first described in PDB and are responsible for
around 30% of familial PDB cases (see [98] for
review). In 2014, Van der Zee et al. published a
large-scale resequencing study in an FTLD cohort of
patients and identified a number of mutations in the
C-terminal of the gene that is involved in the binding
with ubiquitinated proteins [99].
CHCHD10
A coiled-coil-helix-coiled-coil-helix domain con-
taining 10 (CHCHD10) gene encodes a mitochon-
drial protein that is enriched at cristae junctions in
the intermembrane space. By exome sequencing, it
was possible to identify the first pathogenic mutation,
p.S59L, in an atypical family with late onset MND,
FTD, cerebellar ataxia, and mitochondrial myopathy
[100]. Subsequent genetic studies identified addi-
tional potential pathogenic mutation in FTD and ALS
patients with 1–3% frequency [101]. Very recently,
Perrone et al. identified a novel nonsense mutation
(p.Gln108*) in a patient with atypical clinical FTD
and pathology-confirmed Parkinson’s disease (1/459,
0.22%) leading to loss of transcript. They further
observed three previously described missense vari-
ants (p.Pro34Ser, p.Pro80Leu, and p.Pro96Thr) that
were also present in the matched control series [102].
TBK1
In 2015, a large exome sequencing case-control
study identified mutations in the TANK binding
kinase 1 gene (TBK1) in sporadic ALS cohort of
patients [103]. Subsequent studied showed TBK1 loss
of function mutations in families with FTD-ALS but
also in clinical FTD and pathologically confirmed
FTLD-TDP even in the absence of motor neuron
disease [104]. The majority of mutations identified
are loss-of-function mutations leading to a decrease
50% ofTBK1 expression. Missense mutations instead
impair the binding of TBK1 to optineurin (OPTN).
As VCP or p62, TBK1 is also involved in protein
degradation and autophagy mechanisms. In fact, it
phosphorylates p62 and OPTN, another member of
the autophagy pathway. In 2015, Potteir et al. discov-
ered, in a pathologically confirmed cohort of patients,
one heterozygous mutation and one deletion in OPTN
as well as a nonsense mutation in TBK1 suggesting
that both genes contribute to FTLD-TDP etiology
[104].
TARDBP
TARDBP encodes for TDP-43 protein, which is
localized in the nucleus of the cell, where it is
able to form heterogeneous nuclear ribonucleopro-
tein (hnRNP) complexes with several functions, such
as RNA regulation, mRNA stability and transport,
and splicing control. A link between FTLD and ALS
and TDP-43 was supported by the evidence that
TDP-43 regulate axon growth in vivo and in vitro
suggesting that the capacity of motor neuron to pro-
duce and maintain axons is compromised by TDP-43
dysregulation [105].
FUS
Similar to TDP-43, Fused in sarcoma (FUS) is
highly conserved and ubiquitously expressed gene.
FUS is a component of the hnRNP complex and
involved in RNA transport in and out of the nucleus,
RNA splicing, and DNA/RNA metabolism [106]. In
2009, FUS mutations were discovered to be the cause
of 3% of familial ALS. They are mostly located in the
C-terminal of the protein, particularly in the nuclear
localization sequence, resulting in an impairment of
transportin (TRN1)-mediated nuclear import of FUS
[106]. Neuropathologically, ALS patients with FUS
mutations display abnormal cytoplasmic neuronal
and glial inclusions positive for FUS. However, in
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some FTLD-FUS patients, no FUS mutations have
been identified.
UBQLN2
UBQLN2 is involved in a rare form of chromo-
some X-linked familial ALS and FTLD-ALS [107].
Mutations are located in proline residues in the
highly conserved PXXP repeat domain involved in
the degradation of misfolded proteins via ubiquitin
proteasome system and autophagy.
TUBA4A
TUBA4A encodes 1 of 8 human a-tubulins, which
polymerize with b-tubulins to form the microtubule
cytoskeleton. TUBA4A mutations have primarily
been associated with ALS, although some patients
also had cognitive involvement ranging from mild
cognitive impairment to FTD. In TUBA4A, 10 mis-
sense, 1 nonsense, and 1 splice donor site mutation
have been identified in both sporadic and familial
ALS patients, with some also presenting with FTD
[102].
GENETICS OF FRONTOTEMPORAL
DEMENTIA: GENETIC MODIFIERS
In addition to genes mentioned above and generally
involved in familial autosomal dominant transmis-
sion, several genetic risk factors have been studied.
The most important and replicated is the trans-
membrane protein 106b gene (TMEM106B). In
2010, Van Deerlin and coworkers published the first
GWAs on 515 FTD patients with TDP-43 pathol-
ogy; they identified a possible susceptibility locus,
which encompasses TMEM106B gene on chromo-
some 7p21 [108]. In particular, the study identified
three associated single nucleotide polymorphisms
(SNPs), rs102004, rs6966915 and rs1990622, which
are correlated with an increase ofTMEM106B expres-
sion level [108]. Several subsequent studies showed
that the highest association with TMEM106B locus
was found in patients with GRN mutations with TDP-
43 pathology [109, 110]. In GRN mutation carriers,
the presence of protective C allele of SNP rs1990622,
protects these patients from developing FTD [110].
The protective effects of TMEM106B are not con-
fined to carriers of GRN mutations but also extend
to C9ORF72 carriers [111, 112]. TMEM106b is a
glycosylated type 2-membrane protein that localized
to late endosomes and lysosomes where it seems
to have an important function. Over-expression of
TMEM106b in cell cultures showed an aberrant vac-
uole formation and an impairment of endolysosomal
pathway [113].
Common SNPs in the major causal genes have
been studied to determine their association as FTD
risk factors. For example, rs5848, located in 3’UTR
of the GRN gene in a putative miRNA binding site,
has been investigated. Unfortunately, its role remains
unclear with significant association in initial series
of FTD-TDP43 patients but not in subsequent series
of clinical patients [114]. More recently, a two-stage
GWAS identified the HLA locus at chromosome
6p21.3 and a locus at chromosome 11q14 encom-
passing RAB38 and cathepsin C (CTSC) [115]. These
two gene are especially associated with FTD and an
association was observed between the top SNP at
RAB8/CTSC locus and a 50% reduction of RAB8 lev-
els in the blood of patients suggesting that a loss of
RAB8 function may play a role in the development
of FTD. RAB8 is a protein involved in the regula-
tion of lysosomal biology and protein trafficking. The
HLA locus, instead, suggests a link between FTD and
immune system [115].
EPIGENETICS
Epigenetics is focused on the investigation of
mechanisms able to influence the expression of genes
without altering the DNA sequence. DNA methyla-
tion, chromatin remodeling, and non-coding RNAs
(ncRNAs) are the three most investigated epigenetic
modifications [116]. Epigenetic processes are able to
regulate DNA replication and repair, RNA transcrip-
tion, and chromatin conformation, that influence in
turn transcriptional regulation and protein translation.
Methylation
DNA methylation is the best characterized epi-
genetic modification that involves the addition of a
methyl group to the carbon-5 of a cytosine residue
in DNA and is carried out by one of the several
DNA methyltranferase (DNMT) enzymes. DNMT1
is the enzyme responsible for the maintenance of
DNA methylation patterns during DNA replication.
It localizes to the DNA replication fork, where it
methylates nascent DNA strands at the same loca-
tions as in the template strand [117]. DNMT3a and
DNMT3b are involved in the de novo methylation
of unmethylated and hemimethylated sites in nuclear
and mitochondrial DNA, respectively [117, 118].
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In mammals, DNA methylation occurs predomi-
nantly at CpG sites-locations, where a cytosine
nucleotide is followed by a guanine nucleotide. CpG
sites can occur in concentrations of up to several
hundred dinucleotide repeats, called CpG islands,
which are frequently found in gene promoters. The
methylation or hypermethylation of CpG islands usu-
ally prevents the expression of the downstream gene
[119]. DNA methylation is currently the best under-
stood epigenetic mechanisms, and is known to have
a crucial role in normal development, cell prolif-
eration, and genome stability [120]. In addition,
non-CpG methylation may happen in stem cells and
neurons [121].
Early epigenetic investigations related to AD
focused on DNA methylation, finding non AD spe-
cific hypomethylation of the APP gene promoter
region in one patient [122].
More recent studies support an overall reduction
in DNA methylation in AD patients thus highlight-
ing the importance of DNA methylation in AD [123].
Interestingly A has also been implicated as a trig-
ger of epigenetic changes as it was found that A
induces global DNA hypomethylation [124]. More-
over, a DNA methylome paper found genes with
altered methylation in AD brains [125].
Tau gene expression is also subject to complex
epigenetic regulation, involving differentially methy-
lated binding sites for transcription factors [126].
Recently, Bollati and colleagues investigated the
methylation status of repetitive elements in blood,
including Arthrobacter luteus elements (Alu) blood,
long interspersed element 1 (LINE-1), and satellite-
(SAT-), that comprise a wide portion of the human
genome and are known to contain large numbers of
CpG sites. They found that LINE-1 methylation was
increased in AD patients and that enhanced LINE-1
methylation was associated with a better cognitive
performance in AD patients [127].
Regarding FTD, two studies analyzed the GRN
promoter methylation in relation to its ability to
regulate progranulin expression. They found that
increased methylation in FTD subjects negatively
correlates with GRN mRNA levels [128, 129].
A recent GWAS on DNA methylation pattern
in peripheral blood of patients with FTD and pro-
gressive supranuclear palsy compared to healthy
subjects found a specific methylation signature asso-
ciated pathologically with tauopathy, suggesting this
signature as a risk factor for neurodegeneration [130].
Regarding the C9ORF72 expansion, it was sug-
gested that the length of the repeat might influence the
level of DNA methylation at the C9ORF72 promoter.
This process was found in a family from Canada
with the father carrying an intermediate length allele,
about 70 repeats, with an unmethylated C9ORF72
promoter, that expanded to about 1750 repeats in
his children. The expanded allele carried by the
four children was characterized by C9ORF72 pro-
moter hypermethylation and associated with reduced
C9ORF72 expression [131]. Recent findings demon-
strated that DNA hypermethylation was found in the
5’ CpG region (∼36% ALS cases), as well as the
C9ORF72 repeat itself in both ALS and FTD patients
(∼100%) [132, 133].
ncRNAs
It was widely believed in the past that most of the
human genome consisted in “non-functional” DNA.
It was later discovered that almost the whole genome
is transcribed, but that just about 2% in translated into
proteins [134].
It is now instead ascertained that most of this
“junk” is functional and composed by ncRNA, whose
signaling and editing is able to play a crucial role
in chromatin and nuclear structure. In particular,
ncRNAs are involved in epigenetic regulation by
recruiting chromatin-modifying complexes. ncRNAs
operate through repressive control but have also the
potential to act as gene activators [134].
ncRNAs comprise small RNAs (sRNAs) of less
than 200 nucleotides and long non coding RNA
(lncRNAs) of more than 200 nucleotides. sRNAs are
further subdivided as micro (mi)RNAs, short inter-
fering (si)RNAs, and PIWI-associated (pi)RNAs,
whereas lncRNA are categorized according to their
direction and position of their transcription in: anti-
sense, intergenic, exonic, intronic, overlapping [135].
miRNAs are single stranded, non-coding small
RNAs that are abundant in plants and animals,
and are conserved across species [136]. The raw
transcripts undergo several nuclear and cytoplas-
mic post-translation processing steps to generate
mature, functional miRNAs. In the cytoplasm, mature
miRNAs associate with other proteins to form the
RNA-Induced Silencing Complex (RISC), enabling
the miRNA to imperfectly pair with cognate miRNA
transcripts. The target mRNA is then degraded by
the RISC, preventing its translation into protein [137,
138]. miRNA-mediated repression of translation is
involved in many cellular processes, such as differ-
entiation, proliferation, and apoptosis, as well as other
key cellular mechanisms [139, 140].
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It is now well established that altered RNA pro-
cessing could act as a contributing factor to several
neurological conditions including aging-related neu-
rodegenerative diseases such as AD, FTD, ALS, and
Parkinson’s disease [141–143].
In AD, the implication of miRNAs in A
production, via BACE1 modulation, and in tau
phosphorylation, that leads to hyperphosphorylated
neurofibrillary tangle formation, has been demon-
strated [142].
Altered miRNA signatures were also identified in
AD and FTD. In particular, several miRNAs have
identified differentially expressed in postmortem tis-
sue, blood, and CSF that also differ by disease stage
[145, 146].
Regarding lncRNAs, they also have been involved
in neurodegenerative diseases [146].
These ncRNAs are involved in different func-
tions; they act as scaffolds for chromatin modifiers
and nuclear paraspeckles, as transcriptional co-
regulators, and even as decoys for other RNAs [145].
Dysregulations in lncRNAs can influence any one of
these processes, thus contributing to neurodegenera-
tion. lncRNAs associated with disease condition can
post-transcriptionally increase gene expression, as it
happens with the lncRNA BACE1-antisense whose
expression is selectively increased in AD brains
and competes with miR-545-5p binding to stabilize
BACE1 mRNA. This will finally result in increased
expression of BACE1 that contribute to the formation
of the toxic A peptides that is a major hallmark for
AD [146].
Another lncRNA, BC200, likely plays a role in
AD as increased levels were found in specific brain
regions mostly affected by AD, such as the Brod-
mann’s area 9 [147]. MALAT1 and NEAT1 are other
two lncRNAs very important for splicing and synapse
formation [148, 149].
Chromatin remodeling
In mammalian cells, histone proteins interact with
DNA to form chromatin, the packaged form of DNA.
Histones are octamer consisting of two copies of
each of the four histone proteins: H2A, H2B, H3,
and H4. Each histone octamer constitutes in 146 bp
of the DNA stand wound around it to make up one
nucleosome, which is the basic unit of chromatin.
Histone proteins can be modified by post translational
changes, including: acetylation, methylation, phos-
phorylation, ubiquitination, and citrullination. These
histone modifications induce changes to the structure
of chromatin and thereby affect the accessibility of
the DNA strand to transcriptional enzymes, resulting
in activation or repression of genes associated with
the modified histone [150]. The best-understood his-
tone modification is acetylation, which is mediated
by histone acetyltransferases and deacetylases [151].
Acetylation of histones is usually associated with
upregulated transcriptional activity of the associated
gene, whereas deacetylation of histones to transcrip-
tional silencing [152].
Histone acetylation was found to be largely
decreased in the temporal lobe of AD patients com-
pared to controls and in mouse models of AD [153].
Moreover, increased H3 acetylation at the promoter
region of the BACE1 gene in AD patients was found
[153].
Besides acetylation, different forms of histone
methylation exist [154], and may be linked to neu-
rodegenerative diseases.
CONCLUSIONS
Herein, we provided an overview of the current
genetic and epigenetic progresses in AD and FTD.
We reviewed current knowledge on causative genes
and altered mechanisms leading to the two diseases,
genetic risk factors and disease modifiers shown to
influence the age at onset and clinical course of
the diseases, and the role of epigenetics, includ-
ing methylation, non-coding RNAs, and chromatin
remodeling, in influencing gene expression. Data
obtained so far suggest a crucial role of microglia and
immunity in AD and a role of autophagy and protea-
somal degradation in FTD. Future challenges will be
a better understanding of the interplay among genetic
and epigenetic factors in order to correlate pathogenic
mechanisms with clinical phenotypes and pave the
way for novel therapeutic approaches such as miRNA
mimics or miRNA antagonists (antagomirs), specif-
ically designed to either reverse the downregulation
or upregulation of disease-associated miRNAs.
DISCLOSURE STATEMENT
Authors’ disclosures available online (https://
www.j-alz.com/manuscript-disclosures/17-0702r2).
REFERENCES
[1] Frazer KA, Murray SS, Schork NJ, Topol EJ (2009)
Human genetic variation and its contribution to complex
traits. Nat Rev Genet 10, 241-251.
924 C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD
[2] Nakamura Y (2009) DNA variations in human and medical
genetics: 25 years of my experience. J Hum Genet 54, 1-8.
[3] Ku CS, Loy EY, Salim A, Pawitan Y, Chia KS (2010)
The discovery of human genetic variations and their use
as disease markers: Past, present and future. J Hum Genet
55, 403-415.
[4] Kimura, M (1968) Evolutionary rate at the molecular level.
Nature 217, 624-626.
[5] Dawn Teare M, Barrett JH (2005) Genetic linkage studies.
Lancet 366, 1036-1044.
[6] Hattersley AT, McCarthy MI (2005) A question of stan-
dards: What makes a good genetic association study?
Lancet 366, 1315-1323.
[7] Simo´n-Sa´nchez J, Singleton A (2008) Genome-wide asso-
ciation studies in neurological disorders. Lancet Neurol 7,
1067-1072.
[8] Pritchard JK (2001) Are rare variants responsible for sus-
ceptibility to complex diseases? Am J Hum Genet 69,
124-137.
[9] Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ,
Nickerson DA, Shendure J (2011) Exome sequencing as a
tool for Mendelian disease gene discovery. Nat Rev Genet
12, 745-755.
[10] Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE
(2013) Rare-disease genetics in the era of next-generation
sequencing: Discovery to translation. Nat Rev Genet 14,
681-691.
[11] Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis
A, Ward PA, Braxton A, Beuten J, Xia F, Niu Z, Hardi-
son M, Person R, Bekheirnia MR, Leduc MS, Kirby A,
Pham P, Scull J, Wang M, Ding Y, Plon SE, Lupski
JR, Beaudet AL, Gibbs RA, Eng CM (2013) Clinical
whole-exome sequencing for the diagnosis of Mendelian
disorders. N Engl J Med 369, 1502-1511.
[12] Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y,
Ward P, Braxton A, Wang M, Buhay C, Veeraraghavan N,
Hawes A, Chiang T, Leduc M, Beuten J, Zhang J, He W,
Scull J, Willis A, Landsverk M, Craigen WJ, Bekheir-
nia MR, Stray-Pedersen A, Liu P, Wen S, Alcaraz W,
Cui H, Walkiewicz M, Reid J, Bainbridge M, Patel A,
Boerwinkle E, Beaudet AL, Lupski JR, Plon SE, Gibbs
RA, Eng CM (2014) Molecular findings among patients
referred for clinical whole-exome sequencing. JAMA 312,
1870-1879.
[13] Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s
disease. Lancet 368, 387-403.
[14] Lill CM, Bertram L (2011) Towards unveiling the genetics
of neurodegenerative diseases. Semin Neurol 31, 531-541.
[15] Lanoisele´e HM, Nicolas G, Wallon D, Rovelet-Lecrux
A, Lacour M, Rousseau S, Richard AC, Pasquier F,
Rollin-Sillaire A, Martinaud O, Quillard-Muraine M, de
la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx
F, Chauvire´ V, Sarazin M, le Ber I, Epelbaum S, Jon-
veaux T, Rouaud O, Ceccaldi M, Fe´lician O, Godefroy O,
Formaglio M, Croisile B, Auriacombe S, Chamard L, Vin-
cent JL, Sauve´e M, Marelli-Tosi C, Gabelle A, Ozsancak
C, Pariente J, Paquet C, Hannequin D, Campion D, col-
laborators of the CNR-MAJ project (2017) APP, PSEN1,
and PSEN2 mutations in early-onset Alzheimer disease:
A genetic screening study of familial and sporadic cases.
PLoS Med 14, e1002270.
[16] Jarmolowicz AI, Chen HY, Panegyres PK (2014) The pat-
terns of inheritance in early-onset dementia: Alzheimer’s
disease and frontotemporal dementia.AmJAlzheimersDis
Other Demen 30, 299-306.
[17] Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-
Muraine M, Guyant-Mare´chal L, Martinaud O, Pariente J,
Puel M, Rollin-Sillaire A, Pasquier F, Le Ber I, Sarazin M,
Croisile B, Boutoleau-Bretonnie`re C, Thomas-Ante´rion
C, Paquet C, Moreaud O, Gabelle A, Sellal F, Sauve´e
M, Laquerrie`re A, Duyckaerts C, Delisle MB, Streichen-
berger N, Lannes B, Frebourg T, Hannequin D, Campion
D, collaborators of GMAJ project (2012) The French
series of autosomal dominant early onset Alzheimer’s dis-
ease cases: Mutation spectrum and cerebrospinal fluid
biomarkers. J Alzheimers Dis 30, 847-56.
[18] Guerreiro RJ, Lohmann E, Kinsella E, Bra´s JM, Luu N,
Gurunlian N, Dursun B, Bilgic B, Santana I, Hanagasi
H, Gurvit H, Gibbs JR, Oliveira C, Emre M, Singleton A
(2012) Exome sequencing reveals an unexpected genetic
cause of disease: NOTCH3 mutation in a Turkish family
with Alzheimer’s disease. Neurobiol Aging 33, 1008.e17-
23.
[19] Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A,
Wallon D, Rousseau S, Legallic S, Paquet C, Bombois
S, Pariente J, Thomas-Anterion C, Michon A, Croisile
B, Etcharry-Bouyx F, Berr C, Dartigues JF, Amouyel P,
Dauchel H, Boutoleau-Bretonnie`re C, Thauvin C, Fre-
bourg T, Lambert JC, Campion D, PHRC GMAJ Collab-
orators (2012) High frequency of potentially pathogenic
SORL1 mutations in autosomal dominant early-onset
Alzheimer disease. Mol Psychiatry 17, 875-879.
[20] Jiang T, Yu JT, Zhu XC, Tan L (2013) TREM2 in
Alzheimer’s disease. Mol Neurobiol 48, 180-185.
[21] Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A,
Richard AC, Rollin-Sillaire A, Frebourg T, Campion D,
Hannequin D (2013) TREM2 R47H variant as a risk fac-
tor for early-onset alzheimer’s disease. J Alzheimers Dis
35, 45-49.
[22] Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z,
Uphill J, Campbell T, Druyeh R, Mahoney CJ, Rohrer
JD, Kenny J, Lowe J, Leung KK, Barnes J, Clegg SL,
Blair M, Nicholas JM, Guerreiro RJ, Rowe JB, Ponto C,
Zerr I, Kretzschmar H, Gambetti P, Crutch SJ, Warren
JD, Rossor MN, Fox NC, Collinge J, Schott JM, Mead
S (2014) R47H TREM2 variant increases risk of typical
early-onset Alzheimer’s disease but not of prion or fron-
totemporal dementia. Alzheimers Dement 10, 602-608.e4.
[23] Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jon-
sson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey
AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen
OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C,
Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U,
Kong A, Stefansson K (2013) Variant of TREM2 associ-
ated with the risk of Alzheimer’s disease. N Engl J Med
368, 107-116.
[24] Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva
E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin
S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J,
Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan
K, Powell J, St George-Hyslop P, Singleton A, Hardy J,
Alzheimer Genetic Analysis Group (2013) TREM2 vari-
ants in Alzheimer’s disease. N Engl J Med 368, 117-127.
[25] Sims R, van der Lee SJ, Naj AC, Bellenguez C,
Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland
A, Raybould R, Bis JC, Martin ER, Grenier-Boley B,
Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers
K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoff-
mann P, Grove ML, Vardarajan BN, Hiltunen M, No¨then
MM, White CC, Hamilton-Nelson KL, Epelbaum J, Maier
C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD 925
W, Choi SH, Beecham GW, Dulary C, Herms S, Smith
AV, Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H,
Bacq D, Harold D, Satizabal CL, Valladares O, Squassina
A, Thomas R, Brody JA, Qu L, Sa´nchez-Juan P, Morgan
T, Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage
M, Malamon J, Naranjo MCD, Majounie E, Mosley TH,
Dombroski B, Wallon D, Lupton MK, Dupuis J, White-
head P, Fratiglioni L, Medway C, Jian X, Mukherjee
S, Keller L, Brown K, Lin H, Cantwell LB, Panza F,
McGuinness B, Moreno-Grau S, Burgess JD, Solfrizzi
V, Proitsi P, Adams HH, Allen M, Seripa D, Pastor P,
Cupples LA, Price ND, Hannequin D, Frank-Garc´ia A,
Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS,
Giedraitis V, Hampel H, Garcia ME, Wang X, Lannfelt
L, Mecocci P, Eiriksdottir G, Crane PK, Pasquier F, Boc-
cardi V, Hena´ndez I, Barber RC, Scherer M, Tarraga L,
Adams PM, Leber M, Chen Y, Albert MS, Riedel-Heller
S, Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D,
Masullo C, Schmidt H, Doody RS, Spalletta Jr G, WTL,
Fairchild TJ, Bossu´ P, Lopez OL, Frosch MP, Sacchinelli
E, Ghetti B, Yang Q, Huebinger RM, Jessen F, Li S, Kam-
boh MI, Morris J, Sotolongo-Grau O, Katz MJ, Corcoran
C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall
R, Gerrish A, Chapman J, Aguilar M, Taylor S, Hill M,
Faire´n MD, Hodges A, Vellas B, Soininen H, Kloszewska
I, Daniilidou M, Uphill J, Patel Y, Hughes JT, Lord J, Tur-
ton J, Hartmann AM, Cecchetti R, Fenoglio C, Serpente
M, Arcaro M, Caltagirone C, Orfei MD, Ciaramella A,
Pichler S, Mayhaus M, Gu W, Lleo´ A, Fortea J, Blesa R,
Barber IS, Brookes K, Cupidi C, Maletta RG, Carrell D,
Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber J,
Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor B,
Lynch A, Fox NC, Hardy J, ARUK Consortium, Albin
RL, Apostolova LG, Arnold SE, Asthana S, Atwood CS,
Baldwin CT, Barnes LL, Barral S, Beach TG, Becker JT,
Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer A, Burke
JR, Burns JM, Buxbaum JD, Cairns NJ, Cao C, Carl-
son CS, Carlsson CM, Carney RM, Carrasquillo MM,
Carroll SL, Diaz CC, Chui HC, Clark DG, Cribbs DH,
Crocco EA, DeCarli C, Dick M, Duara R, Evans DA, Faber
KM, Fallon KB, Fardo DW, Farlow MR, Ferris S, Foroud
TM, Galasko DR, Gearing M, Geschwind DH, Gilbert
JR, Graff-Radford NR, Green RC, Growdon JH, Hamil-
ton RL, Harrell LE, Honig LS, Huentelman MJ, Hulette
CM, Hyman BT, Jarvik GP, Abner E, Jin LW, Jun G, Kary-
das A, Kaye JA, Kim R, Kowall NW, Kramer JH, LaFerla
FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP,
Lunetta KL, Lyketsos CG, Marson DC, Martiniuk F, Mash
DC, Masliah E, McCormick WC, McCurry SM, McDavid
AN, McKee AC, Mesulam M, Miller BL, Miller CA,
Miller JW, Morris JC, Murrell JR, Myers AJ, O’Bryant S,
Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry
W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF,
Raj A, Raskind M, Reisberg B, Reitz C, Ringman JM,
Roberson ED, Rogaeva E, Rosen HJ, Rosenberg RN, Sager
MA, Saykin AJ, Schneider JA, Schneider LS, Seeley WW,
Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH,
Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso
JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsat-
tel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC,
Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE,
Yu L, Garzia F, Golamaully F, Septier G, Engelborghs
S, Vandenberghe R, De Deyn PP, Fernadez CM, Benito
YA, Thonberg H, Forsell C, Lilius L, Kinhult-Sta¨hlbom A,
Kilander L, Brundin R, Concari L, Helisalmi S, Koivisto
AM, Haapasalo A, Dermecourt V, Fievet N, Hanon O,
Dufouil C, Brice A, Ritchie K, Dubois B, Himali JJ, Keene
CD, Tschanz J, Fitzpatrick AL, Kukull WA, Norton M,
Aspelund T, Larson EB, Munger R, Rotter JI, Lipton RB,
Bullido MJ, Hofman A, Montine TJ, Coto E, Boerwinkle
E, Petersen RC, Alvarez V, Rivadeneira F, Reiman EM,
Gallo M, O’Donnell CJ, Reisch JS, Bruni AC, Royall DR,
Dichgans M, Sano M, Galimberti D, St George-Hyslop
P, Scarpini E, Tsuang DW, Mancuso M, Bonuccelli U,
Winslow AR, Daniele A, Wu CK, GERAD/PERADES,
CHARGE, ADGC, EADI, Peters O, Nacmias B, Riemen-
schneider M, Heun R, Brayne C, Rubinsztein DC, Bras J,
Guerreiro R, Al-Chalabi A, Shaw CE, Collinge J, Mann
D, Tsolaki M, Clarimo´n J, Sussams R, Lovestone S,
O’Donovan MC, Owen MJ, Behrens TW, Mead S, Goate
AM, Uitterlinden AG, Holmes C, Cruchaga C, Ingelsson
M, Bennett DA, Powell J, Golde TE, Graff C, De Jager
PL, Morgan K, Ertekin-Taner N, Combarros O, Psaty BM,
Passmore P, Younkin SG, Berr C, Gudnason V, Rujescu
D, Dickson DW, Dartigues JF, DeStefano AL, Ortega-
Cubero S, Hakonarson H, Campion D, Boada M, Kauwe
JK, Farrer LA, Van Broeckhoven C, Ikram MA, Jones L,
Haines JL, Tzourio C, Launer LJ, Escott-Price V, Mayeux
R, Deleuze JF, Amin N, Holmans PA, Pericak-Vance MA,
Amouyel P, van Duijn CM, Ramirez A, Wang LS, Lam-
bert JC, Seshadri S, Williams J, Schellenberg GD (2017)
Rare coding variants in PLCG2, ABI3, and TREM2 impli-
cate microglial-mediated innate immunity in Alzheimer’s
disease. Nat Genet 49, 1373-1384.
[26] Cacace R, Van den Bossche T, Engelborghs S, Geerts N,
Laureys A, Dillen L, Graff C, Thonberg H, Chiang HH,
Pastor P, Ortega-Cubero S, Pastor MA, Diehl-Schmid J,
Alexopoulos P, Benussi L, Ghidoni R, Binetti G, Nacmias
B, Sorbi S, Sanchez-Valle R, Llado´ A, Gelpi E, Almeida
MR, Santana I, Tsolaki M, Koutroumani M, Clarimon J,
Lleo´ A, Fortea J, de Mendonc¸a, Martins M, Borroni B,
Padovani A, Matej R, Rohan Z, Vandenbulcke M, Van-
denberghe R, De Deyn PP, Cras P, van der Zee J, Sleegers
K, Van Broeckhoven C, Belgium Neurology (BELNEU)
Consortium and the European Early-Onset Dementia (EU
EOD) Consortium (2015) Rare variants in PLD3 do not
affect risk for early-onset Alzheimer disease in a European
Consortium Cohort. Hum Mutat 36, 1226-1235.
[27] Piccoli E, Rossi G, Rossi T, Pelliccioni G, D’Amato I,
Tagliavini F, Di Fede G (2016) Novel PSEN1 mutations
(H214N and R220P) associated with familial Alzheimer’s
disease identified by targeted exome sequencing. Neuro-
biol Aging 40, 192.e7-11.
[28] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull
WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch
N, van Duijn CM (1997) Effects of age, sex, and ethnic-
ity on the association between apolipoprotein E genotype
and Alzheimer disease. A meta-analysis. APOE and
Alzheimer Disease Meta Analysis Consortium. JAMA
278, 1349-1356.
[29] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish
A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,
Williams A, Jones N, Thomas C, Stretton A, Morgan AR,
Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C,
Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K,
Brown KS, Passmore PA, Craig D, McGuinness B, Todd S,
Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy
J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen
F, Schu¨rmann B, Heun R, van den Bussche H, Heuser I,
Kornhuber J, Wiltfang J, Dichgans M, Fro¨lich L, Hampel
926 C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD
H, Hu¨ll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga
C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens
K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Liv-
ingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R,
Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton
AB, Guerreiro R, Mu¨hleisen TW, No¨then MM, Moebus S,
Jo¨ckel KH, Klopp N, Wichmann HE, Carrasquillo MM,
Pankratz VS, Younkin SG, Holmans PA, O’Donovan M,
Owen MJ, Williams J (2009) Genome wide association
study identifies variants at CLU and PICALM associated
with Alzheimer’s disease. Nat Genet 41, 1088-1093.
[30] Hollingworth P, Harold D, Sims R, Gerrish A, Lam-
bert JC, Carrasquillo MM, Abraham R, Hamshere ML,
Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A,
Thomas C, Richards A, Ivanov D, Widdowson C, Chap-
man J, Lovestone S, Powell J, Proitsi P, Lupton MK,
Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A,
Brown KS, Passmore PA, Craig D, McGuinness B, Todd
S, Holmes C, Mann D, Smith AD, Beaumont H, Warden
D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy
ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J,
Maier W, Jessen F, Ru¨ther E, Schu¨rmann B, Heun R,
Ko¨lsch H, van den Bussche H, Heuser I, Kornhuber J,
Wiltfang J, Dichgans M, Fro¨lich L, Hampel H, Gallacher
J, Hu¨ll M, Rujescu D, Giegling I, Goate AM, Kauwe JS,
Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers
K, Bettens K, Engelborghs S, De Deyn PP, Van Broeck-
hoven C, Livingston G, Bass NJ, Gurling H, McQuillin
A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE,
Tsolaki M, Singleton AB, Guerreiro R, Mu¨hleisen TW,
No¨then MM, Moebus S, Jo¨ckel KH, Klopp N, Wichmann
HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M,
Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen
RC, Alzheimer’s Disease Neuroimaging Initiative, van
Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitz-
patrick AL, Lopez O, Launer LJ, Seshadri S, CHARGE
consortium, Berr C, Campion D, Epelbaum J, Dartigues
JF, Tzourio C, Alpe´rovitch A, Lathrop M, EADI1 con-
sortium, Feulner TM, Friedrich P, Riehle C, Krawczak
M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil
S, Steinberg S, Stefansson H, Stefansson K, Snaedal
J, Bjo¨rnsson S, Jonsson PV, Chouraki V, Genier-Boley
B, Hiltunen M, Soininen H, Combarros O, Zelenika D,
Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-
Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco
P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias
B, Sorbi S, Bossu´ P, Piccardi P, Arosio B, Annoni G, Seripa
D, Pilotto A, Scarpini E, Galimberti D, Brice A, Han-
nequin D, Licastro F, Jones L, Holmans PA, Jonsson T,
Riemenschneider M, Morgan K, Younkin SG, Owen MJ,
O’Donovan M, Amouyel P, Williams J (2011) Common
variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33,
and CD2AP are associated with Alzheimer’s disease. Nat
Genet 43, 429-435.
[31] Lupton MK, Proitsi P, Danillidou M, Tsolaki M, Hamilton
G, Wroe R, Pritchard M, Lord K, Martin BM, Kloszewska
I, Soininen H, Mecocci P, Vellas B, Harold D, Holling-
worth P, Lovestone S, Powell JF (2011) Deep sequencing
of the Nicastrin gene in pooled DNA, the identification
of genetic variants that affect risk of Alzheimer’s disease.
PLoS One 6, e17298.
[32] Kohli MA, Cukier HN, Hamilton-Nelson KL, Rolati S,
Kunkle BW, Whitehead PL, Zu¨chner SL, Farrer LA, Mar-
tin ER, Beecham GW, Haines JL, Vance JM, Cuccaro
ML, Gilbert JR, Schellenberg GD, Carney RM, Pericak-
Vance MA (2016) Segregation of a rare TTC3 variant in an
extended family with late-onset Alzheimer disease. Neurol
Genet 2, e41.
[33] Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002)
The prevalence of frontotemporal dementia.Neurology58,
1615-1621.
[34] Bird T, Knopman D, VanSwieten J, Rosso S, Feldman
H, Tanabe H, Graff-Radford N, Geschwind D, Verpil-
lat P, Hutton M (2003) Epidemiology and genetics of
frontotemporal dementia/Pick’s disease. Ann Neurol 54,
S29-S31.
[35] Goldman JS, Farmer JS, Wood EM, Johnson JK, Boxer
A, Neuhaus J, Lomen-Hoerth C, Wilhelmsen KC, Lee
VM, Grossman M, Miller BL (2005) Comparison of fam-
ily histories in FTLD subtypes and related tauopathies.
Neurology 65, 1817-1819.
[36] Pickering-Brown SM (2007) The complex aetiology
of frontotemporal lobar degeneration. Exp Neurol 114,
39-47.
[37] Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defen-
dini RF, Sima AA, Keohane C, Nygaard TG, Fahn S, et
al. (1994) Clinical characteristics of a family with chro-
mosome 17-linked disinhibition-dementia-parkinsonism-
amyotrophy complex. Neurology 44, 1878-1884.
[38] Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S,
Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A,
Grover A, Hackett J, Adamson J, Lincoln S, Dickson D,
Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E,
van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny
P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J,
Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannen-
berg T, Dodd PR, Hayward N, Kwok JB, Schofield PR,
Andreadis A, Snowden J, Craufurd D, Neary D, Owen F,
Oostr, BA, Hardy J, Goate A, van Swieten J, Mann D,
Lynch T, Heutink P (1998) Association of missense and
5′-splice-site mutations in tau with the inherited dementia
FTDP-17. Nature 393, 702-705.
[39] Wang Y, Mandelkow E (2015) Tau in physiology and
pathology. Nat Rev Neurosci 17, 22-35.
[40] Neve RL, Harris P, Kosik K, Kurnit DM, Donlon TA (1986)
Identification of cDNA clones for the human microtubule
associated protein tau and chromosomal localization of the
genes for tau and microtubule-associated protein 2. Brain
Res 387, 271-280.
[41] Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson
BC, Goedert M (2015) Invited review: Frontotemporal
dementia caused by microtubule-associated protein tau
gene (MAPT) mutations: A chameleon for neuropathol-
ogy and neuroimaging. Neuropathol Appl Neurobiol 41,
24-46.
[42] Rademakers R, Cruts M, van Broeckhoven C (2004) The
role of tau (MAPT) in frontotemporal dementia and related
tauopathies. Hum Mutat 24, 277-295.
[43] Malkani R, D’Souza I, Gwinn-Hardy K, Schellenberg GD,
Hardy J, Momeni P (2006) A MAPT mutation in a regula-
tory element upstream of exon 10 causes frontotemporal
dementia. Neurobiol Dis 22, 401-403.
[44] Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek
Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D,
Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD,
Trojanowski JQ, Lee VM (1998) Mutation-specific func-
tional impairments in distinct Tau isoforms of hereditary
FTDP-17. Science 282, 1914-1917.
[45] Goedert M, Jakes R, Crowther RA (1999) Effects of
frontotemporal dementia FTDP-17 mutations on heparin-
C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD 927
induced assembly of tau filaments. FEBS Lett 450,
306-311.
[46] Rovelet-Lecrux A, Lecourtois M, Thomas-Anterion C, Le
Ber I, Brice A, Frebourg T, Hannequin D, Campion D
(2009) Partial deletion of the MAPT gene: A novel mech-
anism of FTDP-17. Hum Mutat 30, 591-602.
[47] Rovelet-Lecrux A, Hannequin D, Guillin O, Legallic S,
Jurici S, Wallon D, Frebourg T, Campion D (2010) Fron-
totemporal dementia phenotype associated with MAPT
gene duplication. J Alzheimers Dis 21, 897-902.
[48] Mann DMA, Snowden JS (2017) Frontotemporal lobar
degeneration: Pathogenesis, pathology and pathways to
phenotype. Brain Pathol 27, 723-736.
[49] Baker M, Mackenzie IR, Pickering-Brown SM, Gass J,
Rademakers R, Lindholm C, Snowden J, Adamson J,
Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary
D, Melquist S, Richardson A, Dickson D, Berger Z,
Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R,
McGowan E, Mann D, Boeve B, Feldman H, Hutton M
(2006) Mutations in progranulin cause tau-negative fron-
totemporal dementia linked to chromosome 17. Nature
442, 916-919.
[50] Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils
H, Pirici D, Rademakers R, Vandenberghe R, Dermaut
B, Martin JJ, van Duijn C, Peeters K, Sciot R, San-
tens P, De Pooter T, Mattheijssens M, Van den Broeck
M, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S,
Van Broeckhoven C (2006) Null mutations in progranulin
cause ubiquitin-positive frontotemporal dementia linked
to chromosome 17q21. Nature 442, 920-924.
[51] Rademakers R, Neumann M, Mackenzie IR (2012)
Advances in understanding the molecular basis of fron-
totemporal dementia. Nat Rev Neurol 8, 423-434.
[52] Petkau TL, Leavitt BR (2014) Progranulin in neurodegen-
erative disease. Trends Neurosci 37, 388-398.
[53] Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M,
Adamson J, Crook R, Melquist S, Kuntz K, Petersen R,
Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti
R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio
E, Johnson N, Weintraub S, Mesulam M, White 3rd CL,
Woodruff B, Caselli R, Hsiung GY, Feldman H, Knopman
D, Hutton M, Rademakers R (2006) Mutations in progran-
ulin are a major cause of ubiquitin-positive frontotemporal
lobar degeneration. Hum Mol Genet 15, 2988-3001.
[54] Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB,
Steinbart E, Galloway NM, Feldman H, Woltjer R, Miller
CA, Wood EM, Grossman M, McCluskey L, Clark CM,
Neumann M, Danek A, Galasko DR, Arnold SE, Chen-
Plotkin A, Karydas A, Miller BL, Trojanowski JQ, Lee
VM, Schellenberg GD, Van Deerlin VM (2010) The spec-
trum of mutations in progranulin: A collaborative study
screening 545 cases of neurodegeneration. Arch Neurol
67, 161-170.
[55] Neumann M, Sampathu DM, Kwong LK, Truax AC,
Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman
M, Clark CM, McCluskey LF, Miller BL, Masliah E,
Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA,
Trojanowski JQ, Lee VM (2006) Ubiquitinated TDP-43
in frontotemporal lobar degeneration and amyotrophic lat-
eral sclerosis. Science 314, 130-133.
[56] Mackenzie IR, Neumann M, Baborie A, Sampathu DM,
Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann
DM, Lee VM (2011) A harmonized classification sys-
tem for FTLD-TDP pathology. Acta Neuropathol 122,
111-113.
[57] Benussi A, Padovani A, Borroni B (2015) Phenotypic het-
erogeneity of monogenic frontotemporal dementia. Front
Aging Neurosci 7, 171.
[58] Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj
E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot
F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol
J, Deramecourt V, Lejeune P, de la Sayette V, Belliard S,
Vercelletto M, Meyrignac C, Van Broeckhoven C, Lambert
JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice
A, French research network on FTD/FTD-MND (2008)
Phenotype variability in progranulin mutation carriers: A
clinical, neuropsychological, imaging and genetic study.
Brain 131, 732-746.
[59] Rainero I, Rubino E, Negro E, Gallone S, Galimberti
D, Gentile S, Scarpini E, Pinessi L (2011) Heterosex-
ual pedophilia in a frontotemporal dementia patient with
a mutation in the progranulin gene. Biol Psychiatry 70,
43-44.
[60] Cerami C, Marcone A, Galimberti D, Villa C, Scarpini
E, Cappa SF (2011) From genotype to phenotype: Two
cases of genetic frontotemporal lobar degeneration with
premorbid bipolar disorder. J Alzheimers Dis 27, 791-797.
[61] Pietroboni AM, Fumagalli GG, Ghezzi L, Fenoglio C,
Cortini F, Serpente M, Cantoni C, Rotondo E, Corti P,
Carecchio M, Bassi M, Bresolin N, Galbiati D, Galimberti
D, Scarpini E (2011) Phenotypic heterogeneity of the GRN
Asp22fs mutation in a large Italian kindred. J Alzheimers
Dis 24, 253-259.
[62] Bruni AC, Momeni P, Bernardi L, Tomaino C, Frangipane
F, Elder J, Kawarai T, Sato C, Pradella S, Wakutani Y,
Anfossi M, Gallo M, Geracitano S, Costanzo A, Smirne N,
Curcio SA, Mirabelli M, Puccio G, Colao R, Maletta RG,
Kertesz A, St George-Hyslop P, Hardy J, Rogaeva E (2007)
Heterogeneity within a large kindred with frontotemporal
dementia: A novel progranulin mutation. Neurology 69,
140-147.
[63] Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G
(2008) Low plasma progranulin levels predict progranulin
mutations in frontotemporal lobar degeneration. Neurol-
ogy 71, 1235-1239.
[64] Carecchio M, Fenoglio C, De Riz M, Guidi I, Comi C,
Cortini F, Venturelli E, Restelli I, Cantoni C, Bresolin N,
Monaco F, Scarpini E, Galimberti D (2009) Progranulin
plasma levels as potential biomarker for the identification
of GRN deletion carriers. A case with atypical onset as
clinical amnestic Mild Cognitive Impairment converted to
Alzheimer’s disease. J Neurol Sci 287, 291-293.
[65] Pickford F, Marcus J, Camargo LM, Xiao Q, Graham
D, Mo JR, Burkhardt M, Kulkarni V, Crispino J, Her-
ing H, Hutton M (2011) Progranulin is a chemoattractant
for microglia and stimulates their endocytic activity. Am J
Pathol 178, 284-295.
[66] Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed
NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH,
Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng
JQ, Abramson SB, Yu XP, Liu CJ (2011) The growth
factor progranulin binds to TNF receptors and is thera-
peutic against inflammatory arthritis in mice. Science 332,
478-484.
[67] Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi
SM, Fumagalli G, Arighi A, Ghezzi L, Arcaro M, Mer-
curio M, Rotondo E, Scarpini E (2015) Inflammatory
molecules in Frontotemporal Dementia: Cerebrospinal
fluid signature of progranulin mutation carriers. Brain
Behav Immun 49, 182-187.
928 C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD
[68] Hosler BA, Siddique T, Sapp PC, Sailor W, Huang MC,
Hossain A, Daube JR, Nance M, Fan C, Kaplan J, Hung
WY, McKenna-Yasek D, Haines JL, Pericak-Vance MA,
Horvitz HR, Brown Jr RH (2000) Linkage of familial amy-
otrophic lateral sclerosis with frontotemporal dementia to
chromosome 9q21–q22. JAMA 284, 1664-1669.
[69] Morita M, Al-Chalabi A, Andersen PM, Hosler B, Sapp P,
Englund E, Mitchell JE, Habgood JJ, de Belleroche J, Xi J,
Jongjaroenprasert W, Horvitz HR, Gunnarsson LG, Brown
Jr RH (2006) A locus on chromosome 9p confers suscep-
tibility to ALS and frontotemporal dementia. Neurology
66, 839-844.
[70] DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer
AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA,
Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung
GY, Karydas A, Seeley WW, Josephs KA, Coppola G,
Geschwind DH, Wszolek ZK, Feldman H, Knopman DS,
Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-
Radford NR, Rademakers R (2011) Expanded GGGGCC
hexanucleotide repeat in noncoding region of C9ORF72
causes chromosome 9p-linked FTD and ALS. Neuron 72,
245-256.
[71] Renton AE, Majounie E, Waite A, Simo´n-Sa´nchez J,
Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van
Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abram-
zon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth
J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok
K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal
J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar
H, Blake D, Young K, Halliwell N, Callister JB, Toul-
son G, Richardson A, Gerhard A, Snowden J, Mann D,
Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita
VM, Kaivorinne AL, Ho¨ltta¨-Vuori M, Ikonen E, Sulkava
R, Benatar M, Wuu J, Chio` A, Restagno G, Borghero
G, Sabatelli M, ITALSGEN Consortium, Heckerman D,
Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drep-
per C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra
A, Pak E, Hardy J, Singleton A, Williams NM, Heutink
P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ
(2011). A hexanucleotide repeat expansion in C9ORF72 is
the cause of chromosome 9p21-linked ALS-FTD. Neuron
72, 257-268.
[72] van Blitterswijk M, DeJesus-Hernandez M, Niemantsver-
driet E, Murray ME, Heckman MG, Diehl NN, Brown
PH, Baker MC, Finch NA, Bauer PO, Serrano G, Beach
TG, Josephs KA, Knopman DS, Petersen RC, Boeve
BF, Graff-Radford NR, Boylan KB, Petrucelli L, Dick-
son DW, Rademakers R (2013) Association between
repeat sizes and clinical and pathological characteristics
in carriers of C9ORF72 repeat expansions (Xpansize-
72): A cross-sectional cohort study. Lancet Neurol 12,
978-988.
[73] Ishiura H, Tsuji S (2015) Epidemiology and molec-
ular mechanism of frontotemporal lobar degenera-
tion/amyotrophic lateral sclerosis with repeat expansion
mutation in C9orf72. J Neurogenet 29, 85-94.
[74] Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T,
Wray S, Sidle K, Fratta P, Orrell RW, Hardy J, Holton J,
Revesz T, Rossor MN, Warren JD (2015) C9orf72 expan-
sions in frontotemporal dementia and amyotrophic lateral
sclerosis. Lancet Neurol 14, 291-301.
[75] Cooper-Knock J, Kirby J, Highley R, Shaw PJ (2015)
The spectrum of C9orf72-mediated neurodegeneration
and amyotrophic lateral sclerosis. Neurotherapeutics 12,
326-339.
[76] Snowden JS, Rollinson S, Thompson JC, Harris JM, Stop-
ford CL, Richardson AM, Jones M, Gerhard A, Davidson
YS, Robinson A, Gibbons L, Hu Q, DuPlessis D, Neary
D, Mann DM, Pickering-Brown SM (2012) Distinct clin-
ical and pathological characteristics of frontotemporal
dementia associated with C9ORF72 mutations. Brain 135,
693-708.
[77] Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi
R, Arighi A, Fumagalli GG, Del Bo R, Bruni AC,
Anfossi M, Clodomiro A, Cupidi C, Nacmias B, Sorbi
S, Piaceri I, Bagnoli S, Bessi V, Marcone A, Cerami C,
Cappa SF, Filippi M, Agosta F, Magnani G, Comi G,
Franceschi M, Rainero I, Giordana MT, Rubino E, Fer-
rero P, Rogaeva E, Xi Z, Confaloni A, Piscopo P, Bruno
G, Talarico G, Cagnin A, Clerici F, Dell’Osso B, Comi
GP, Altamura AC, Mariani C, Scarpini E (2013) Auto-
somal dominant Frontotemporal Lobar Degeneration due
to the C9ORF72 hexanucleotide repeat expansion: Late-
onset psychotic clinical presentation. Biol Psychiatry 74,
384-391.
[78] Galimberti D, Reif A, Dell’osso B, Kittel-Schneider S,
Leonhard C, Herr A, Palazzo C, Villa C, Fenoglio C, Ser-
pente M, Cioffi SM, Prunas C, Paoli RA, Altamura AC,
Scarpini (2014) C9ORF72 hexanucleotide repeat expan-
sion is a rare cause of schizophrenia. Neurobiol Aging 35,
1214 e1217-1214 e1210.
[79] Galimberti D, Reif A, Dell’Osso B, Palazzo C, Villa C,
Fenoglio C, Kittel-Schneider S, Leonhard C, Olmes DG,
Serpente M, Paoli RA, Altamura AC, Scarpini E (2014)
C9ORF72 hexanucleotide repeat expansion as a rare cause
of bipolar disorder. Bipolar Disord 16, 448-449.
[80] Majounie E, Abramzon Y, Renton AE, Perry R, Bas-
sett SS, Pletnikova O, Troncoso JC, Hardy J, Singleton
AB, Traynor BJ (2012) Repeat expansion in C9ORF72 in
Alzheimer’s disease. N Engl J Med 366, 283-284.
[81] Xi Z, Zinman L, Grinberg Y, Moreno D, Sato C, Bilbao JM,
Ghani M, Herna´ndez I, Ruiz A, Boada M, Moro´n FJ, Lang
AE, Marras C, Bruni A, Colao R, Maletta RG, Puccio G,
Rainero I, Pinessi L, Galimberti D, Morrison KE, Moorby
C, Stockton JD, Masellis M, Black SE, Hazrati LN, Liang
Y, van Haersma de With J, Fornazzari L, Villagra R, Rojas-
Garcia R, Clarimo´n J, Mayeux R, Robertson J, St George-
Hyslop P, Rogaeva E (2012) Investigation of c9orf72 in 4
neurodegenerative disorders. Arch Neurol 69, 1583-1590.
[82] Mori K, Arzberger T, Gra¨sser FA, Gijselinck I, May S,
Rentzsch K, Weng SM, Schludi MH, van der Zee J, Cruts
M, Van Broeckhoven C, Kremmer E, Kretzschmar HA,
Haass C, Edbauer D (2013) Bidirectional transcripts of
the expanded C9orf72 hexanucleotide repeat are trans-
lated into aggregating dipeptide repeat proteins. Acta
Neuropathol 126, 881-893.
[83] Haeusler AR, Donnelly CJ, Rothstein JD (2016) The
expanding biology of the C9orf72 nucleotide repeat
expansion in neurodegenerative disease. Nat Rev Neurosci
17, 383-395.
[84] Reddy K, Zamiri B, Stanley SY, Macgregor RB, Pearson
CE (2013) The disease-associated r(GGGGCC)n repeat
from the C9ORF72 gene forms tract length-dependent uni-
and multi-molecular RNA G-quadruplex structures. J Biol
Chem 88, 9860-9866.
[85] Mizielinska S, Isaacs AM (2014) C9orf72 amyotrophic
lateral sclerosis and frontotemporal dementia: Gain or loss
of function? Curr Opin Neurol 27, 515-523.
[86] Gijselinck I, Van Mossevelde S, van der Zee J, Sieben
A, Engelborghs S, De Bleecker J, Ivanoiu A, Deryck O,
C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD 929
Edbauer D, Zhang M, Heeman B, Ba¨umer V Van den
Broeck M, Mattheijssens M, Peeters K, Rogaeva E, De
Jonghe P, Cras P, Martin JJ, de Deyn PP, Cruts M, Van
Broeckhoven C (2016) The C9orf72 repeat size correlates
with onset age of disease, DNA methylation and transcrip-
tional downregulation of the promoter. Mol Psychiatry 21,
1112-1124.
[87] May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch
K, Schwenk BM, Gra¨sser FA, Mori K, Kremmer E,
Banzhaf-Strathmann J, Mann M, Meissner F, Edbauer D
(2014) C9orf72 FTLD/ALS associated Gly-Ala dipep-
tide repeat proteins cause neuronal toxicity and Unc119
sequestration. Acta Neuropathol 128, 485-503.
[88] van Blitterswijk M, Rademakers R (2015) Neu-
rodegenerative disease: C9orf72 repeats compromise
nucleocytoplasmic transport. Nat Rev Neurol 11, 670-672.
[89] Lehmer C, Oeckl P, Weishaupt JH, Volk AE, Diehl-
Schmid J, Schroeter ML, Lauer M, Kornhuber J, Levin
J, Fassbender K, Landwehrmeyer B, German Consor-
tium for Frontotemporal Lobar Degeneration, Schludi
MH, Arzberger T, Kremmer E, Flatley A, Feederle
R, Steinacker P, Weydt P, Ludolph AC, Edbauer D,
Otto M (2017) Poly-GP in cerebrospinal fluid links
C9orf72-associated dipeptide repeat expression to the
asymptomatic phase of ALS/FTD. EMBO Mol Med 9,
859-868.
[90] Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L,
Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillan-
tini MG, Thusgaard T, Brandner S, Brun A, Rossor
MN, Gade A, Johannsen P, Sørensen SA, Gydesen S,
Fisher EM, Collinge J (2005) Mutations in the endosomal
ESCRTIII-complex subunit CHMP2B in frontotemporal
dementia. Nat Genet 37, 806-808.
[91] Urwin H, Ghazi-Noori S, Collinge J, Isaacs A (2009) The
role of CHMP2B in frontotemporal dementia. Biochem
Soc Trans 37, 208-212.
[92] Lindquist SG, Braedgaard H, Svenstrup K, Isaacs AM,
Nielsen JE, FReJA Consortium (2008) Frontotemporal
dementia linked to chromosome 3 (FTD-3)-current con-
cepts and the detection of a previously unknown branch
of the Danish FTD-3 family. Eur J Neurol 15, 667-670.
[93] Urwin H, Authier A, Nielsen JE, Metcalf D, Powell C,
Froud K, Malcolm DS, Holm I, Johannsen P, Brown J,
Fisher EM, van der Zee J, Bruyland M, FReJA Consor-
tium, Van Broeckhoven C, Collinge J, Brandner S, Futter
C, Isaacs AM (2010) Disruption of endocytic trafficking in
frontotemporal dementia with CHMP2B mutations. Hum
Mol Genet 19, 2228-2238.
[94] Isaacs AM, Johannsen P, Holm I, Nielsen JE, FReJA
consortium (2011) Frontotemporal dementia caused by
CHMP2B mutations. Curr Alzheimer Res 8, 246-251.
[95] Watts GD, J Wymer J, Kovach MJ, Mehta SG, Mumm
S, Darvish D, Pestronk A, Whyte MP, Kimonis VE
(2004) Inclusion body myopathy associated with Paget
disease of bone and frontotemporal dementia is caused
by mutant valosincontaining protein. Nat Genet 36,
377-381.
[96] Spina S, Van Laar AD, Murrell JR, Hamilton RL, Kofler
JK, Epperson F, Farlow MR, Lopez OL, Quinlan J,
DeKosky ST, Ghetti B (2013) Phenotypic variability in
three families with valosin-containing protein mutation.
Eur J Neurol 20, 251-258.
[97] Ju J-S, Weihl CC (2010) Inclusion body myopathy, Paget’s
disease of the bone and fronto-temporal dementia: A dis-
order of autophagy. Hum Mol Genet 19, R38-R45.
[98] Ng ASL, Rademakers R, Miller BL (2015) Frontotemporal
dementia: A bridge between dementia and neuromuscular
disease. Ann N Y Acad Sci 1338, 71-93.
[99] Rea SL, Majcher V, Searle MS, Layfield R (2014)
SQSTM1 mutations–bridging Paget disease of bone and
ALS/FTLD. Exp Cell Res 325, 27-37.
[100] van der Zee J, Van Langenhove T, Kovacs GG, Dillen
L, Deschamps W, Engelborghs S, Mateˇj R, Vandenbul-
cke M, Sieben A, Dermaut B, Smets K, Van Damme P,
Merlin C, Laureys A, Van Den Broeck M, Mattheijssens
M, Peeters K, Benussi L, Binetti G, Ghidoni R, Borroni
B, Padovani A, Archetti S, Pastor P, Razquin C, Ortega-
Cubero S, Herna´ndez I, Boada M, Ruiz A, de Mendonc¸a A,
Miltenberger-Milte´nyi G, do Couto FS, Sorbi S, Nacmias
B, Bagnoli S, Graff C, Chiang HH, Thonberg H, Perneczky
R, Diehl-Schmid J, Alexopoulos P, Frisoni GB, Bonvicini
C, Synofzik M, Maetzler W, vom Hagen JM, Scho¨ls
L, Haack TB, Strom TM, Prokisch H, Dols-Icardo O,
Clarimo´n J, Lleo´ A, Santana I, Almeida MR, Santiago
B, Heneka MT, Jessen F, Ramirez A, Sanchez-Valle R,
Llado A, Gelpi E, Sarafov S, Tournev I, Jordanova A,
Parobkova E, Fabrizi GM, Testi S, Salmon E, Stro¨bel T,
Santens P, Robberecht W, De Jonghe P, Martin JJ, Cras P,
Vandenberghe R, De Deyn PP, Cruts M, Sleegers K, Van
Broeckhoven C (2014) Rare mutations in SQSTM1 mod-
ify susceptibility to frontotemporal lobar degeneration.
Acta Neuropathol 128, 397-410.
[101] Bannwarth S, Ait-El-Mkadem S, Chaussenot A, Genin
EC, Lacas-Gervais S, Fragaki K, Berg-Alonso L,
Kageyama Y, Serre V, Moore DG, Verschueren A, Rouzier
C, Le Ber I, Auge´ G, Cochaud C, Lespinasse F, N’Guyen
K, de Septenville A, Brice A, Yu-Wai-Man P, Sesaki H,
Pouget J, Paquis-Flucklinger V (2014) A mitochondrial
origin for frontotemporal dementia and amyotrophic lat-
eral sclerosis through CHCHD10 involvement. Brain 137,
2329-2345.
[102] Zhang M, Xi Z, Zinman L, Bruni AC, Maletta RG, Curcio
SA, Rainero I, Rubino E, Pinessi L, Nacmias B, Sorbi S,
Galimberti D, Lang AE, Fox S, Surace EI, Ghani M, Guo
J, Sato C, Moreno D, Liang Y, Keith J, Traynor BJ, St
George-Hyslop P, Rogaeva E (2015) Mutation analysis of
CHCHD10 in different neurodegenerative diseases. Brain
138(Pt 9), e380.
[103] Perrone F, Nguyen HP, Van Mossevelde S, Moisse M,
Sieben A, Santens P, De Bleecker J, Vandenbulcke M,
Engelborghs S, Baets J, Cras P, Vandenberghe R, De
Jonghe P, De Deyn PP, Martin JJ, Van Damme P, Van
Broeckhoven C, van der Zee J, Belgian Neurology con-
sortium (2017) Investigating the role of ALS genes
CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum
patients. Neurobiol Aging 51, 177.e9-177.
[104] Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA,
Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ,
Ren Z, Keebler J, Han Y, Levy SE, Boone BE, Wimbish
JR, Waite LL, Jones AL, Carulli JP, Day-Williams AG,
Staropoli JF, Xin WW, Chesi A, Raphael AR, McKenna-
Yasek D, Cady J, Vianney de Jong JM, Kenna KP, Smith
BN, Topp S, Miller J, Gkazi A, FALS Sequencing Consor-
tium, Al-Chalabi A, van den Berg LH, Veldink J, Silani
V, Ticozzi N, Shaw CE, Baloh RH, Appel S, Simpson
E, Lagier-Tourenne C, Pulst SM, Gibson S, Trojanowski
JQ, Elman L, McCluskey L, Grossman M, Shneider NA,
Chung WK, Ravits JM, Glass JD, Sims KB, Van Deerlin
VM, Maniatis T, Hayes SD, Ordureau A, Swarup S, Lan-
ders J, Baas F, Allen AS, Bedlack RS, Harper JW, Gitler
930 C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD
AD, Rouleau GA, Brown R, Harms MB, Cooper GM, Har-
ris T, Myers RM, Goldstein DB (2015) Exome sequencing
in amyotrophic lateral sclerosis identifies risk genes and
pathways. Science 347, 1436-1441.
[105] Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker
M, Perkersen R, Brown P, Ravenscroft T, van Blitter-
swijk M, Nicholson AM, DeTure M, Knopman DS,
Josephs KA, Parisi JE, Petersen RC, Boylan KB, Boeve
BF, Graff-Radford NR, Veltman JA, Gilissen C, Murray
ME, Dickson DW, Rademakers R (2015) Whole-genome
sequencing reveals important role for TBK1 and OPTN
mutations in frontotemporal lobar degeneration without
motor neuron disease. Acta Neuropathol 130, 77-92.
[106] Rainero I, Rubino E, Michelerio A, D’Agata F, Gentile S,
Pinessi L (2017) Recent advances in the molecular genet-
ics of frontotemporal lobar degeneration. Funct Neurol 32,
7-16.
[107] Neumann M, Valori CF, Ansorge O, Kretzschmar HA,
Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bil-
bao JM, Mackenzie IR (2012) Transportin 1 accumulates
specifically with FET proteins but no other transportin
cargos in FTLD-FUS and is absent in FUS inclusions
in ALS with FUS mutations. Acta Neuropathol 124,
705-716.
[108] Dillen L, Van Langenhove T, Engelborghs S, Vanden-
bulcke M, Sarafov S, Tournev I, Merlin C, Cras P,
Vandenberghe R, De Deyn PP, Jordanova A, Cruts M,
Van Broeckhoven C, van der Zee J, BELNEU consor-
tium (2013) Explorative genetic study of UBQLN2 and
PFN1 in an extended Flanders-Belgian cohort of fron-
totemporal lobar degeneration patients. Neurobiol Aging
34, 1711.e1-1711.e5.
[109] Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-
Plotkin A, Wang LS, Graff-Radford NR, Dickson DW,
Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann
DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swi-
eten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges
J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA,
Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes
C, Rosenberg RN, White CL 3rd, Ferrer I, Llado´ A, Neu-
mann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer
KA, Miller BL, Alzualde A, Lopez de Munain A, McKee
AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD,
Lashley T, Mackenzie IR, Feldman HH, Hamilton RL,
Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeck-
hoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ,
Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ,
Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG,
Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano
M, Bennett DA, Schneider JA, Beach TG, Reiman EM,
Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui
HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D,
Masliah E, Cotman CW, Tun˜o´n MT, Mart´inez MC, Munoz
DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N,
Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee
VM. (2010). Common variants at 7p21 are associated with
frontotemporal lobar degeneration with TDP-43 inclu-
sions. Nat Genet 42, 234-239.
[110] Finch N, Carrasquillo MM, Baker M, Rutherford NJ,
Coppola G, Dejesus-Hernandez M, Crook R, Hunter T,
Ghidoni R, Benussi L, Crook J, Finger E, Hantanpaa KJ,
Karydas AM, Sengdy P, Gonzalez J, Seeley WW, John-
son N, Beach TG, Mesulam M, Forloni G, Kertesz A,
Knopman DS, Uitti R, White 3rd CL, Caselli R, Lippa C,
Bigio EH, Wszolek ZK, Binetti G, Mackenzie IR, Miller
BL, Boeve BF, Younkin SG, Dickson DW, Petersen RC,
Graff-Radford NR, Geschwind DH, Rademakers R (2011)
TMEM106B regulates progranulin levels and the pene-
trance of FTLD in GRN mutation carriers. Neurology 76,
467-474.
[111] Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs
AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Mor-
ris JC, Goate A (2011) Association of TMEM106B gene
polymorphism with age at onset in granulin mutation car-
riers and plasma granulin protein levels. Arch Neurol 68,
581-586.
[112] Gallagher MD, Suh E, Grossman M, Elman L, McCluskey
L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E,
Ghetti B, Rohrer JD, Halliday G, Van Broeckhoven C,
Seilhean D, Shaw PJ, Frosch MP, Alafuzoff I, Antonell
A, Bogdanovic N, Brooks W, Cairns NJ, Cooper-Knock
J, Cotman C, Cras P, Cruts M, De Deyn PP, DeCarli C,
Dobson-Stone C, Engelborghs S, Fox N, Galasko D, Gear-
ing M, Gijselinck I, Grafman J, Hartikainen P, Hatanpaa
KJ, Highley JR, Hodges J, Hulette C, Ince PG, Jin LW,
Kirby J, Kofler J, Kril J, Kwok JB, Levey A, Lieberman
A, Llado A, Martin JJ, Masliah E, McDermott CJ, McKee
A, McLean C, Mead S, Miller CA, Miller J, Munoz DG,
Murrell J, Paulson H, Piguet O, Rossor M, Sanchez-Valle
R, Sano M, Schneider J, Silbert LC, Spina S, van der Zee
J, Van Langenhove T, Warren J, Wharton SB, White CL
3rd, Woltjer RL, Trojanowski JQ, Lee VM, Van Deerlin V,
Chen-Plotkin AS (2014) TMEM106B is a genetic modi-
fier of frontotemporal lobar degeneration with C9orf72
hexanucleotide repeat expansions. Acta Neuropathol 127,
407-418.
[113] van Blitterswijk M, Mullen B, Nicholson AM, Bieniek
KF, Heckman MG, Baker MC, DeJesus-Hernandez M,
Finch NA, Brown PH, Murray ME, Hsiung GY, Stewart
H, Karydas AM, Finger E, Kertesz A, Bigio EH, Wein-
traub S, Mesulam M, Hatanpaa KJ, White CL 3rd, Strong
MJ, Beach TG, Wszolek ZK, Lippa C, Caselli R, Petru-
celli L, Josephs KA, Parisi JE, Knopman DS, Petersen
RC, Mackenzie IR, Seeley WW, Grinberg LT, Miller BL,
Boylan KB, Graff-Radford NR, Boeve BF, Dickson DW,
Rademakers R (2014) TMEM106B protects C9ORF72
expansion carriers against frontotemporal dementia. Acta
Neuropathol 127, 397-406.
[114] Brady OA, Zheng Y, Murphy K, Huang M, Hu F
(2013) The frontotemporal lobar degeneration risk fac-
tor, TMEM106B, regulates lysosomal morphology and
function. Hum Mol Genet 22, 685-695.
[115] Rollinson S, Rohrer JD, van der Zee J, Sleegers K, Mead
S, Engelborghs S, Collinge J, De Deyn PP, Mann DM, Van
Broeckhoven C, Pickering-Brown SM (2011) No associ-
ation of PGRN 30UTR rs5848 in frontotemporal lobar
degeneration. Neurobiol Aging 32, 754-755.
[116] Ferrari R, Hernandez DG, Nalls MA, Rohrer JD,
Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS,
Schofield PR, Halliday GM, Hodges JR, Piguet O, Bartley
L, Thompson E, Haan E, Herna´ndez I, Ruiz A, Boada M,
Borroni B, Padovani A, Cruchaga C, Cairns NJ, Benussi L,
Binetti G, Ghidoni R, Forloni G, Galimberti D, Fenoglio
C, Serpente M, Scarpini E, Clarimo´n J, Lleo´ A, Blesa R,
Waldo¨ ML, Nilsson K, Nilsson C, Mackenzie IR, Hsiung
GY, Mann DM, Grafman J, Morris CM, Attems J, Grif-
fiths TD, McKeith IG, Thomas AJ, Pietrini P, Huey ED,
Wassermann EM, Baborie A, Jaros E, Tierney MC, Pastor
P, Razquin C, Ortega-Cubero S, Alonso E, Perneczky R,
Diehl-Schmid J, Alexopoulos P, Kurz A, Rainero I, Rubino
C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD 931
E, Pinessi L, Rogaeva E, St George-Hyslop P, Rossi G,
Tagliavini F, Giaccone G, Rowe JB, Schlachetzki JC,
Uphill J, Collinge J, Mead S, Danek A, Van Deerlin VM,
Grossman M, Trojanowski JQ, van der Zee J, Deschamps
W, Van Langenhove T, Cruts M, Van Broeckhoven C,
Cappa SF, Le Ber I, Hannequin D, Golfier V, Vercelletto
M, Brice A, Nacmias B, Sorbi S, Bagnoli S, Piaceri I,
Nielsen JE, Hjermind LE, Riemenschneider M, Mayhaus
M, Ibach B, Gasparoni G, Pichler S, Gu W, Rossor MN,
Fox NC, Warren JD, Spillantini MG, Morris HR, Rizzu
P, Heutink P, Snowden JS, Rollinson S, Richardson A,
Gerhard A, Bruni AC, Maletta R, Frangipane F, Cupidi
C, Bernardi L, Anfossi M, Gallo M, Conidi ME, Smirne
N, Rademakers R, Baker M, Dickson DW, Graff-Radford
NR, Petersen RC, Knopman D, Josephs KA, Boeve BF,
Parisi JE, Seeley WW, Miller BL, Karydas AM, Rosen H,
van Swieten JC, Dopper EG, Seelaar H, Pijnenburg YA,
Scheltens P, Logroscino G, Capozzo R, Novelli V, Puca
AA, Franceschi M, Postiglione A, Milan G, Sorrentino P,
Kristiansen M, Chiang HH, Graff C, Pasquier F, Rollin
A, Deramecourt V, Lebert F, Kapogiannis D, Ferrucci
L, Pickering-Brown S, Singleton AB, Hardy J, Momeni
P (2014) Frontotemporal dementia and its subtypes:
A genome-wide association study. Lancet Neurol 13,
686-699.
[117] Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenet-
ics in human disease and prospects for epigenetic therapy.
Nature 429, 457-463.
[118] Goll MG, Bestor TH (2005) Eukaryotic cytosine methyl-
transferases. Annu Rev Biochem 74, 481-514.
[119] Okano M, Bell DW, Haber, DA, Li E (1999) DNA methyl-
transferases Dnmt3a and Dnmt3b are essential for de novo
methylation and mammalian development. Cell 99, 247-
257.
[120] Klose RJ, Bird AP (2006) Genomic DNA methylation:
The mark and its mediators. Trends BiochemSci 31, 89-97.
[121] Weber M, Schu¨beler D (2007) Genomic patterns of DNA
methylation: Targets and function of an epigenetic mark.
Curr Opin Cell Biol 19, 273-280.
[122] Guo JU, Su Y, Shin JH, Shin J, Li H, Xie B, Zhong C,
Hu S, Le T, Fan G, Zhu H, Chang Q, Gao Y, Ming GL,
Song H (2013) Distribution, recognition and regulation of
non-CpG methylation in the adult mammalian brain. Nat
Neurosci 17, 215-222.
[123] West RL, Lee JM, Maroun LE (1995) Hypomethylation
of the amyloid precursor protein gene in the brain of an
Alzheimer’s disease patient. J Mol Neurosci 6, 141-146.
[124] Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman
PD, Rogers J (2010) Epigenetic changes in Alzheimer’s
disease: Decrements in DNA methylation. Neurobiol
Aging 31, 2025-2037.
[125] Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, Hu
CJ (2009) The epigenetic effects of amyloid-beta(1–40)
on global DNA and neprilysin genes in murine cerebral
endothelial cells. Biochem Biophys Res Commun 378,
57-61.
[126] De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalk-
wyk LC, Yu L, Eaton ML, Keenan BT, Ernst J, McCabe
C, Tang A, Raj T, Replogle J, Brodeur W, Gabriel S, Chai
HS, Younkin C, Younkin SG, Zou F, Szyf M, Epstein
CB, Schneider JA, Bernstein BE, Meissner A, Ertekin-
Taner N, Chibnik LB, Kellis M, Mill J, Bennett DA
(2014) Alzheimer’s disease: Early alterations in brain
DNA methylation at ANK1, BIN1, RHBDF2 and other
loci. Nat Neurosci 17, 1156-1163.
[127] Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Ukitsu
M, Genda Y (1999) The methylation status of cytosines in
a tau gene promoter region alters with age to downregulate
transcriptional activity in human cerebral cortex. Neurosci
Lett 275, 89-92.
[128] Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta
F, Cortini F, Scarpini E, Bertazzi PA, Baccarelli A (2011)
DNA methylation in repetitive elements and Alzheimer
disease. Brain Behav Immun 25, 1078-1083.
[129] Banzhaf-Strathmann J, Claus R, Mucke O, Rentzsch K,
van der Zee J, Engelborghs S, De Deyn PP, Cruts M,
van Broeckhoven C, Plass C, Edbauer D (2013) Pro-
moter DNA methylation regulates progranulin expression
and is altered in FTLD. Acta Neuropathol Commun
1, 16.
[130] Galimberti D, D’Addario C, Dell’osso B, Fenoglio C, Mar-
cone A, Cerami C, Cappa SF, Palazzo MC, Arosio B, Mari
D, Maccarrone M, Bresolin N, Altamura AC, Scarpini E
(2013) Progranulin gene (GRN) promoter methylation is
increased in patients with sporadic frontotemporal lobar
degeneration. Neurol Sci 34, 899-903.
[131] Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A,
Geschwind MD, Rosen HJ, Boxer AL, Guo W, Pelle-
grini M, Horvath S, Miller BL, Geschwind DH, Coppola
G (2014) An epigenetic signature in peripheral blood
associated with the haplotype on 17q21.31, a risk factor
for neurodegenerative tauopathy. PLoS Genet 10,
e1004211.
[132] Xi Z, van Blitterswijk M, Zhang M, McGoldrick P,
McLean JR, Yunusova Y, Knock E, Moreno D, Sato C,
McKeever P, Schneider R, Keith J, Petrescu N, Fraser P,
Tartaglia MC, Baker MC, Graff-Radford NR, Boylan KB,
Dickson DW, Mackenzie IR, Rademakers R, Robertson
J, Zinman L, Rogaeva E (2015) Jump from pre-mutation
to pathologic expansion in C9orf72. Am J Hum Genet 96,
962-970.
[133] Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, Maletta
RG, Nacmias B, Sorbi S, Galimberti D, Surace EI, Zheng
Y, Moreno D, Sato C, Liang Y, Zhou Y, Robertson J,
Zinman L, Tartaglia MC, St George-Hyslop P, Rogaeva
E (2014) Hypermethylation of the CpG-island near the
C9orf72 G(4)C(2)-repeat expansion in FTLD patients.
Hum Mol Genet 23, 5630-5637.
[134] Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, Fratta P,
Polke JM, Sweeney MG, Mudanohwo E, Nacmias B, Sorbi
S, Tartaglia MC, Rainero I, Rubino E, Pinessi L, Galim-
berti D, Surace EI, McGoldrick P, McKeever P, Moreno D,
Sato C, Liang Y, Keith J, Zinman L, Robertson J, Rogaeva
E (2015) The C9orf72 repeat expansion itself is methy-
lated in ALS and FTLD patients. Acta Neuropathol 129,
715-727.
[135] Amaral PP, Dinger ME, Mercer TR, Mattick JS (2008)
The eukaryotic genome as an RNA machine. Science 319,
1787-1789.
[136] Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S,
Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG,
Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T,
Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas
M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ,
Notredame C, Harrow J, Guigo´ R (2012) The GENCODE
v7 catalog of human long noncoding RNAs: Analysis of
their gene structure, evolution, and expression. Genome
Res 22, 1775-1789.
[137] Bernstein E, Allis CD (2005). RNA meets chromatin.
Genes Dev 19, 1635-1655.
932 C. Fenoglio et al. / Role of genetics and epigenetics in AD and FTD
[138] Hwang H-W, Mendell JT (2006) MicroRNAs in cell pro-
liferation, cell death, and tumorigenesis. Br J Cancer 94,
776-780.
[139] Sevignani C, Calin GA, Siracusa LD, Croce CM (2006)
Mammalian microRNAs: A small world for fine-tuning
gene expression. Mamm Genome 17, 189-202.
[140] Chang T-C, Mendell JT (2007) MicroRNAs in vertebrate
physiology and human disease. Annu Rev Genomics Hum
Genet 8, 215-239.
[141] Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA
(2007) Regulatory mechanisms of microRNAs involve-
ment in cancer. Expert Opin Biol Ther 7, 1009-1019.
[142] Belzil VV, Gendron TF, Petrucelli L (2013) RNA-
mediated toxicity in neurodegenerative disease. Mol Cell
Neurosci 56, 406-419.
[143] Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash
S, Rothman R, Sierksma AS, Thathiah A, Greenberg D,
Papadopoulou AS, Achsel T, Ayoubi T, Soreq H, Verhaa-
gen J, Swaab DF, Aerts S, De Strooper B (2013) Alteration
of the microRNA network during the progression of
Alzheimer’s disease. EMBO Mol Med 5, 1613-1634.
[144] Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L,
Cioffi SM, Arighi A, Fumagalli G, Scarpini E (2014) Cir-
culating miRNAs as potential biomarkers in Alzheimer’s
disease. J Alzheimers Dis 42, 1261-1267.
[145] Fenoglio C, Ridolfi E, Galimberti D, Scarpini E (2013) An
emerging role for long non-coding RNA dysregulation in
neurological disorders. Int J Mol Sci 14, 20427-20442.
[146] Prensner JR, Chinnaiyan AM (2011) The emergence of
lncRNAs in cancer biology. Cancer Discov 1, 391-407.
[147] Faghihi MA, Modarresi F, Khalil AM, Wood DE, Saha-
gan BG, Morgan TE, Finch CE, St Laurent 3rd G, Kenny
PJ, Wahlestedt C (2008) Expression of a noncoding
RNA is elevated in Alzheimer’s disease and drives rapid
feed-forward regulation of beta-secretase. Nat Med 14,
723-730.
[148] Mus E, Hof PR, Tiedge H (2007) Dendritic BC200 RNA
in aging and in Alzheimer’s disease. Proc Natl Acad Sci
U S A 104, 10679-10684.
[149] Bernard D, Prasanth KV, Tripathi V, Colasse S, Naka-
mura T, Xuan Z, Zhang MQ, Sedel F, Jourdren L, Coulpier
F, Triller A, Spector DL, Bessis A (2010) A long nucle-
arretained non-coding RNA regulates synaptogenesis by
modulating gene expression. EMBO J 29, 3082-3093.
[150] Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT,
Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe
BJ, Prasanth SG, Prasanth KV (2010) The nuclear-retained
noncoding RNA MALAT1 regulates alternative splicing
by modulating SR splicing factor phosphorylation. Mol
Cell 39, 925-938.
[151] Dieker J, Muller S (2010) Epigenetic histone code and
autoimmunity. Clin Rev Allergy Immunol 39, 78-84.
[152] Brooks WH, Le Dantec C, Pers JO, Youinou P,
Renaudineau Y (2010) Epigenetics and autoimmunity.
J Autoimmun 34, J207-J219.
[153] Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H,
Kirsch W (2012) Targeted proteomics for quantification
of histone acetylation in Alzheimer’s disease. Proteomics
12, 1261-1268.
[154] Marques S, Lemos R, Ferreiro E, Martins M, de Mendonca
A, Santana I, Outeiro T, Pereira C (2012) Epigenetic reg-
ulation of BACE1 in Alzheimer’s disease patients and in
transgenic mice. Neuroscience 220, 256-266.
[155] Araki Y, Mimura T (2017) The histone modification code
in the pathogenesis of autoimmune diseases. Mediators
Inﬂamm 2017, 2608605.
